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CHAPTER I 
INTRODUCTION 
Cirrhosis of the liver is associated with profound endo-
crinological disturbances. Until recently it was thought 
that these disturbances were caused mainly by ineffective 
elimination of hormones by the diseased liver. It is now 
known that the pathogenesis of disturbed hormonal function 
in liver cirrhosis is rather more complex, as, in many in-
stances, it involves disturbed secretion and feedback 
mechanisms as well. In fact, in liver disease the metabo-
lic clearance rate of sex-steroids for instance is not 
significantly altered (1,2). The most striking hormonal 
syndrome associated with cirrhosis of the liver is the 
feminization process which occurs in up to 40-50% of male 
patients (1,3). This syndrome is characterized by gyne-
comastia, a feminine distribution of hair, palmar erythema, 
the formation of spider nevi, disturbed gonadal function, 
impotence and infertility. The role of changes in androgen 
and estrogen metabolism in causing this syndrome has been 
the subject of extensive research in recent years and has 
been elucidated to a large extent (4,5,6,7,8,9,10,11,12). 
It is by no means certain, however, that the disturbed 
androgen and estrogen metabolism accounts for all the 
signs and symptoms found in this syndrome. It seemed in-
teresting in this respect to look at possible disturbances 
in the synthesis, release and metabolism of prolactin 
(PRL). Prolactin, a polypeptide hormone, secreted by the 
anterior pituitary, plays a physiological role in breast 
development and lactation. When produced in excess it may 
lead to sterility, amenorrhea and loss of libido. In re-
cent years sensitive radioimmunoassays for the determina-
tion of prolactin in plasma have become available, thus 
facilitating the study of prolactin metabolism and function 
in health and disease. 
This thesis describes an attempt to elucidate the effect 
of liver disease on the synthesis, release and metabolism 
of prolactin. 
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CHAPTER 2 
PROLACTIN A REVIEW OF THE LITERATURE. 
In 1928 Stricker and Grueter (1) reported that injection 
of cow pituitary extract induced lactation in pseudo-
pregnant rabbits. Later, it was established by Riddle and 
Bates (2) that the adenohypophysis was responsible for 
crop milk pDduction in pigeons and for mammary gland 
secretion in mammals. 
In 1941 Astwood (3) demonstrated that the effectiveness 
of pituitary extracts in maintaining functional corpora 
lutea in rats was due to a substance, which they called 
lutetrophin. Although knowledge of its structure and 
physiological role in mammals steadily advanced, it is 
only since 1970 that this hormone has been definitely 
indentified and measured in human blood (4) as a hormone 
with lactogenic properties which is distinct from human 
growth hormone. In 1971 Friesen et al (5) developed the 
first radioimmunoassay of human prolactin and measured 
its serum concentration. Since then the study of the 
physiology and pathology of human prolactin has increased 
steadily. 
In 1977 Shome and Parlow (6) finally established the com-
plete amino acid sequence of prolactin. 
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BIOLOGIC ACTIONS OF PROLACTIN IN MAN. 
More than a hundred different physiologic effects of 
prolactin have been described in vertebrates (7). These 
effects can be divided into five main categories: 
- effects on the breast and on lactation 
- effects on gonadal function 
- effects on fluid and electrolyte balance 
- effects on growth 
- effects on adrenal function 
Although a wealth of knowledge on the function of prolac-
tin in vertebrates has been accumulated, knowledge about 
its specific functions in man is still deficient. As many 
possible actions of prolactin remain highly speculative, 
I will confine myself to those actions that have now been 
established with some certainty in man. 
Effects on breast and lactation. 
In contrast to the situation in several other species 
prolactin does not seem to be essential for the normal 
development of the ductal system of the human breast (8). 
However, prolactin, together with gonadal steroids and 
probably with adrenal steroids, insulin and thyroid hor-
mones, is essential for the initiation and maintenance of 
lactation in humans (8,9). During pregnancy prolactin le-
vels steadily increase (10). Breast enlargement takes pla-
ce under the influence of the increased plasma concentra-
tions of prolactin, estrogens, progesterone and human 
placentary lactogen. The estrogens and progesterone pro-
duced by the placenta are eliminated post partum, and this 
results in an acute change in the prolactin/sexhormone 
ratio. It is this change that leads t,o milk secretion (11). 
Lactation can be inhibited by both estrogens and the pro-
lactin inhibitor, bromocriptine, in the post partum period 
(12). There is a good relationship between lactation and 
the prolactin response to suckling in the first days after 
parturition. In a group of rural African women, who 
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traditionally breast feed their children for 2 years or 
until the arrival of the next child, basal prolactin levels 
fall in the first 3 months, then remain stable for 
approximately 12 months, after which they fall to normal 
concentrations (13). It is probably through these elevated 
but slowly decreasing prolactin levels that breast feeding 
leads to a relative infertility and spacing of children 
(14), although a direct effect of the nursing stimulus is 
also important. 
Effects on the gonadal function in the human male. 
Prolactin receptors have been found in the testis, epi-
dydimis, prostate and seminal vesicles (15,16,17). Prolac-
tin has been suggested to influence testosterone secretion 
through inhibition of the conversion of testosterone to 
dihydrotestosterone by the enzyme 5 x reductase (18). Al-
though not effective on its own, prolactin combined with 
gonadotropins was reported to enhance testosterone produc-
tion (19,20) and combined with testosterone to regulate 
prostatic and seminal vesicular function (21). In the 
human male the actions of prolactin are dependent on its 
concentration : low or normal prolactin levels are neces-
sary for normal testosterone secretion, but elevated pro-
lactin levels reduce it (22). Elevated prolactin levels 
are associated with loss of libido and impotence, which 
can be succesfully treated by reducing these prolactin 
levels with bromocriptine (23) ,whereas bromocriptine has 
no effect on impotence without elevated prolactin levels 
(24). 
Effects on gonadal function in the human female. 
Prolactin receptors have been identified in the ovaries 
of different species, including humans (25). The site of 
action seems to be situated at the LH receptor (26). In 
vitro studies in human cultured granulosa cells have 
shown that high levels of prolactin decrease progesterone 
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production, and that neutralisation of prolactin with 
rabbit antihuman prolactin serum leads to a significant 
decrease in progesterone production (27). This is another 
example of a bell shaped dose response curve in which low/ 
normal concentrations of prolactin are necessary for nor-
mal granulosa cell functions but excess prolactin produc-
tion leads to a block of progesterone production. Increa-
sing levels of prolactin in the circulation result at 
first in a short luteal phase, then in irregular cycles 
and finally in amenorrhea (28). Prolactin levels are 
slightly higher in women than in men (29). Although many 
women do not show clear menstrual cycle-related changes 
in the plasma prolactin concentration, evidence is now 
accumulating that such a relationship does exist. Al-
though the levels can be very variable because of pulsa-
tile release, prolactin concentrations tend to be lowest 
in the early follicular phase of the menstrual cycle, in-
crease in the late follicular phase to a peak around 
ovulation and then decrease in the luteal phase to levels 
which are still above follicular phase levels (30,31). 
These changes in PRL concentrations seem to be related to 
similar changes in estrogen levels but not to changes in 
the plasma levels of progesterone, LH or FSH. In fact, 
women on sequential contraceptives show elevated prolactin 
levels in the estrogen phase which normalize in the com-
bined estrogen/progestagen phase ( 32). 
Prolactin levels rise steadily during pregnancy, reaching 
a maximum in the third trimester (10). These increasing 
levels are most likely caused by the high circulating es-
trogen levels during pregnancy. After parturition,basal 
prolactin levels return to prepartum levels and, without 
suckling, are back to normal within two weeks. Apart from 
increases in serum prolactin levels very high prolactin 
concentrations (36-1800 ng/ml) are found in the amniotic 
fluid (10,33). The amniotic fluid PRL levels increase 
rapidly from the 12th to the 24th week of pregnancy and 
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tend to decrease in the last 6 weeks of pregnancy, although 
they remain about 10 times higher than the maternal plasma 
levels. There is evidence that prolactin in the amniotic 
fluid is secreted by decidual tissue (34), which may also 
explain the very high prolactin levels found in the plasma 
of patients with hydatiform moles. The regulation of 
amniotic prolactin secretion seems to be different from 
that of plasma prolactin, as bromocriptin during pregnancy 
suppresses both maternal and fetal plasma levels but does 
not influence amniotic fluid levels (35). The function of 
this amniotic fluid prolactin remains unclear, although 
a possible role for prolactin in the amniotic fluid osmo-
lar balance has been suggested (36). 
Effects on fluid and electrolyte balance. 
Although prolactin is of great importance in the mainte-
nance of fluid and electrolyte homeostasis in many lower 
vertebrate animals (7) , its effect on fluid and electro-
lyte balance in man is unclear and controversial. 
Prolactin receptors in the kidney of rats and mice are 
concentrated in the proximal tubular cells (37,38), which 
may indicate a possible renal action of prolactin on 
sodium and water metabolism. Earlier studies indicated a 
possible antidiuretic effect of prolactin in humans throuqh 
retention of sodium and water (39,40,41). Later studies, 
however, failed to show an effect of prolactin on tubular 
sodium and water metabolism either directly (42,43,44) or 
through interference with aldosterone secretion (45,46). 
Effects on growth. 
About half of the reported actions of prolactin in all 
classes of vertebrates, including mammals, deal with the 
effects on growth and metamorphosis of various tissues (7) 
In fact the action of prolactin on growth is similar to 
that of growth hormone itself, albeit weaker. 
In humans a possible effect of prolactin on growth is much 
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less clear. Patients with hyperprolactinemia do not develop 
acromegaly, while prolactin does not seem to play a role 
in somatomedin production. It is therefore unlikely that 
prolactin plays an important role in growth in man except 
for a possible effect of prolactin on fetal lung maturation 
and surfacant production (48). It was reported that the 
incidence of respiratory distress syndrome was much higher 
in babies whose umbilical cord prolactin levels were less 
than 200 ng/ml (48). Other workers however have shown 
that normal lung maturation is compatible with very low 
fetal plasma prolactin levels at birth (49). 
Effects on adrenal function. 
The adrenals have also been found to have a very high 
affinity for prolactin (50). Forbes et al (51) reported 
in 1954 that the 24 hour urinary ketosteroid excretion 
was often increased in patients with the galactorrhoea-
amenorrhoea syndrome. Later it was shown that a correla-
tion exists between basal plasma prolactin and 
dihydroepiandrosterone-sulfate ( DHEAS) levels (52). 
Prolonged prolactin elevation together with normal ACTH 
production leads to enhanced DI!EAS production by the adre-
nal cortex (53). However no effect of prolactin suppression 
during pregnancy on plasma DIIEAS values has been found 
both in mothers and newborns (54), which may indicate that 
prolactin is not an important regulatory factor in the 
synthesis of androgen precursors by the renal adrenal 
gland. 
Prolactin probably docs not play a role in the regulation 
of aldosterone secretion. Bromocriptine failed to prevent 
the potassium- induced aldosterone rise between dialysis 
in patients with renal insufficiency (55). Bromocriptine 
also did not influence aldosterone responses to changes 
in posture (35). The suppression of prolactin secretion 
by L-dopa or the stimulation of prolactin secretion with 
TRH did not influence aldosterone secretion (46), while 
metoclopramide elevated prolactin levels but did not chan-
ge aldosterone levels (56). 
Prolactin has corticotropic effects in lower animal forms 
and is an important factor in steroidgenesis in lower 
vertebrates (57). However in man evidence for an effect 
of prolactin·on cortisol secretion is scanty. Ingvarsson 
(58) claimed that ovine prolactin restored the adrenal 
responsiveness of a woman to exogenous ACTH in a patient 
after steroid therapy, while it has been shown that pro-
lacti~ potentiates the effect of ACTH on steroid release 
by cultured adrenal cells and partially restores cortico-
sterone synthesis in hypophysectomised animals (59). On 
the other hand shortterm administration of corticosteroids 
can partially suppress plasma prolactin levels in man (60), 
probably through interference of corticosteroids with pro-
lactin release at a supra hypophyseal level (61). 
In Cushing- s disease, however, prolactin levels have been 
reported to be either normal (62) or slightly elevated 
( 63). 
Miscellaneous effects. 
Evidence has been put forward that prolactin may play a 
role in the regulation of vitamin D metabolism in the 
kidney (64). Spanos et al found that in the chicken pro-
lactin stimulated 1.25 dihydroxy cholecalciferol produc-
tion by enzyme induction (65), while 1.25 dihydroxy chole-
calciferol levels are elevated in the lactating rat (66). 
It is attractive to speculate about a role for prolactin 
in the changes in calcium absorption which take place 
during pregnancy and the puerperium. although direct evi-
dence isaill lacking. In this respect it is interesting 
that parathyroid hormone can elevate plasma prolactin when 
infused in normal subjects (67), while calcitonine admini-
stration (68) and calcium administration (69) have been 
shown to inhibit prolactin release. The latter has been 
suggested to occur through stimulation of hypothalamic 
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dopamin release (69). 
Behavioural effects of prolactin. 
Although a fair amount of evidence is available for the 
existence of a " parental behaviour " inducing effect in 
the fowl and in rodents (70,71) no such evidence is avail-
able at present in larger mammals or in man. 
THE NATURE OF PROLACTIN 
Physical properties and patterns of secretion. 
In 1971 Guyda and Friesen were the first to separate mon-
key prolactin from growth hormone by a chromatographic 
method (72). Shortly thereafter the isolation and purifi-
cation of human prolactin from the pituitary gland by 
Sephadex gel filtration and disc electrophoresis, was re-
ported (73). Radioirnrnunoassays for prolactin were subse-
quently developed (5), which were so sensitive that relia-
ble measurements of plasma prolactin concentrations became 
possible both in physiological and pathological circum-
stances (74). 
Although the structure of animal prolactin has already 
been known for more than 10 years, it was only in 1977 
that Shame and Parlow reported the entire linear aminoacid 
sequence of human prolactin, comprising 198 residues (6). 
The molecular weight is about 21.000 dalton and the struc-
ture shows a 73% identity of amino acid sequence when 
compared to ovine PRL, 77% compared to porcine and 60% 
compared to rat prolactin. Although prolactin has approxi-
mately the same molecular weight as human growth hormone 
large differences exist in the amino acid sequence as only 
32 of the 198 residues are the same (16%). Gelfiltration 
and electrophoresis studies of purified prolactin prepara-
tions reveal substantial heterogeneity (75,76,77). 
It appears that both in plasma (78) and in the pituitary 
(79) three molecular size forms of prolactin are present. 
The most important is the monomeric form which represents 
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approximately 75-80% of total prolactin. The second form 
is probably a dimer and has a molecular weight of approxi-
mately 40.000. It can be detected both in plasma and in 
the pituitary as up to 10-15% of total prolactin. Finally 
a polymeric "big,big" prolactin can be detected represen-
ting-approximately 5% of the total amount in most instan-
ces. It appears that the monomeric fraction in plasma and 
in the pituitary increases in response to stimuli of pro-
lactin SPcretinn (TRH, pregnancv, pneroerium) (78), while 
the "hig.bia" compounil levels decrease after TRH stimula-
tion {79). Alt-hongh t-he monomeric form is nsu"'llly predomi-
nant in prolactinomas, it appears that some tumours may 
preferentially secrete "big,big" prolactin (80). It is not 
known wheter this "big,big" form is merely a polymeric 
form (81) or wheter it should be considered a prohormone 
( 7 9) • 
All forms appear to have similar receptor binding and im-
munological properties suggesting that the biochemical and 
the clinical significance of this heterogeneity is proba-
bly low. 
Normal levels and patterns of secretion. 
Normal levels. 
At birth prolactin levels are as high as 200-300 ng/ml. 
They rapidly fall to a plateau of approximately 100 ng/ml 
which is maintained for several weeks postpartum before 
further declining to about 10 ng/ml at 1 year (29). 
···Before puberty prolactin levels are the same in males and 
females and do not differ from male adults (29,83). How-
ever, during late puberty a significant increase in serum 
prolactin levels takes place in girls probably because of 
the stimulatory effect of estrogens (84). In premenopausal 
women prolactin levels than remain (29) but tend to de-
crease after the menopause. Furthermore prolactin levels 
in both males and females decline with advancing age (85), 
while the prolactin response to TRH also tends to decline 
( 86) • 
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Levels durinq the menstrual cvcle. 
It has been reported that normally menstruating women 
show a consistent midcycle peak of prolactin with slightly 
higher prolactin levels in the luteal phase compared to 
the follicular phase (87). These changes are probably se-
condary to fluctuations in estradiol secretion and with-
out functional meaning. 
24 hour secretory pattern. 
Like other pituitary hormones prolactin secretion follows 
a-nyctherneral rhythm. The increase in prolactin secretion 
is not related to a day and night rhythm, but to sleep 
(88). Prolactin levels rise after falling asleep and fall 
in the morning. Furthermore intrasleep fluctuations in 
prolactin secretion exist and prolactin levels are lowest 
during rapid eye movement (REM) sleep (89), thus sugges-
ting a causal relationship between REM sleep and the re-
lease o~ factors influencing prolactin secretion. Suppres-
sion of prolactin secretion during sleep does not disturb 
REM sleep, which suggests that prolactin does not influen-
ce normal sleep processes (90). 
Apart from this diurnal secretory rhythm prolactin secre-
tion has a pulsatory nature, characterised by the presence 
of frequent peaks, which increase in amplitude during 
sleep (88,91). 
Other physiological stimuli of prolactin secretion. 
Probably the strongest physiologic stimulus for prolactin 
secretion is suckling and nipple manipulation (4,5,92). 
This reflex is clearly important for the iniation and 
maintenance of lactation and is effected by a neuroen-
docrine reflex. Self stimulation of the nipples in non 
puerperal women usually does not elevate prolactin levels 
although stimulation by a sexual partner may elevate pro-
lactin levels (92). There are some reports that prolactin 
levels may rise in women during sexual intercourse with 
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orgasm (93). A second strong physiologic stimulus for pro-
lactin release is found by both physical and psychological 
stress (93,94,95) including anesthesia and minor and major 
surgical interventions (93,96). 
CONTROL OF PROLACTIN SECRETION. 
Introduction. 
In contrast to other pituitary hormones, prolactin secre-
tion is under tonic inhibitory control by the hypothala-
mus. In 1954 L.Desclin and Everett (93.96) demonstrated 
that secretion of all pituitary hormones is reduced after 
disconnection of the pituitary gland from the hypothala-
mus except for prolactin which is secreted in excess. 
Pituitaries transplanted under the renal capsule stop all 
hormone production except that of prolactin which is re-
leased. Exogenous prolactin injected in rats leads to a 
decrease in the circulatory prolactin concentrations, but 
not in animals with a pituitary gland transplanted under 
the renal capsule (99). When the original pituitary was 
left in situ in rats with pituitary transplants, it de-
creased in weight and prolactin content (100). This sug-
gests that a feedback mechanism exists which is mediated 
through the hypothalamus. Apart from this hypothalamic 
factor inhibiting prolactin secretion (PIF) evidence has 
been presented that hypothalamic factors may lead to in-
creased PRL secretion (PRF) (101,102). In addition high 
estrogen levels, wheter from exogenous or endogenous 
sources, stimulate prolactin secretion both in animals 
and in man (95,103,104) through an effect at the hypotha-
lamic and/or at the pituitary level (105,106,107). 
Finally, there is increasing evidence for the existence 
of a neurohormonal negative feedback loop in which prolac-
tin regulates its own synthesis and release through an 
effect on the activity of hypothalamic dopaminergic 
neurons (104,129). 
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The nature of the prolactin inhibiting factor(s). 
Pituitary stalk transection increases prolactin secretion 
in man (98). As early as 1963 it had been found that the 
rat pituitary gland in culture continues to secrete pro-
lactin (108), while coincubation with hypothalamic frag-
ments or extracts decreases prolactin secretion (109,110). 
This suggests that the hypothalamus secretes a prolactin 
inhibiting factor. Later it was found that prolactin re-
lease could be inhibited in vitro by coincubation with 
both dopamine (DA) and also to some extent with norepine-
phrine (111,112,113,114), and that this effect could be 
prevented by DA receptor blocking drugs. 
It was shown that hypothalamic dopamine is directly re-
leased into the pituitary portal capillary bed (115,116, 
117) and that dopamine receptors are present on prolactin 
secreting cells in the pituitary gland (118,119,120). 
Beside these in vitro studies several in vivo studies 
using continuous infusions of dopamine have been perfor-
med. Dopamine infused at a rate of 4 ug/kg/min induced an 
immediate suppression of circulating prolactin in normal 
men and women (121). In a recent study by de Greef and 
Neill (122) it was found that pituitary stalk dopamine 
concentrations, within the physiologic range, signifi-
cantly inhibited prolactin secretion. These and other 
reports (104) leave little doubt that dopamine is the most 
important PIF. 
In 1976 Schally et al found after extraction of half a 
million pig hypothalami, that the fraction with the 
highest PIF activity contained dopamine and norepine-
phrine but was devoid of other polypeptides, thus sugges-
ting that dopamine may be the only PIF (123). However 
other studies have provided evidence that hypothalamic 
extracts devoid of catecholamines, may still have PIF 
activity (124). Schally, using extracts from porcine hypo-
thalami, presented evidence that gamma amino butyric acid 
(GABA) may also have PIF activity (125). They found that 
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both natural and synthetic GABA inhibited prolactin re-
lease in vitro in a dose- dependent way and that this in-
hibition could not be blocked by perphenazine, a dopamine 
agonist which reverses the prolactin inhibiting effect of 
dopamine. However these findings have not been confirmed 
in other studies in which no (126) or only a slight PIF 
effect (127,128) of GABA was found. 
Ehe nature of the prolactin releasing factors (PRF). 
Apart from a diminished inhibition by dopamine, increased 
prolactin secretion may also be due to an increased se-
cretion of hypothalamic prolactin releasing factor(s) 
(PRF). Valverde et al (129) extracted a porcine hypotha-
lamic fraction able to stimulate prolactin secretion. At 
the same time it was discovered that thyrotropin releasing 
factor (TRH) stimulated prolactin release in vitro (130), 
thus suggesting that TRH might be a PRF. In humans TRH 
also leads to an immediate increase in prolactin secretion. 
During suckling serum PRL rises but not TSH (131), which 
suggests that TRH cannot be the only PRF. 
TRH receptors are present on both thyrotropic and lacto-
tropic cells in the pituitary gland (132) and administra-
tion of antiserum against synthetic TRH leads to a 50-70% 
decrease of both TSH and prolactin levels in rats (133). 
Thus, although not the only PRF, TRH seems to be important 
in the control of prolactin secretion. Serotonin and es-
trogens have also been suggested to be physiologically 
important PRF-s and will be discussed later. Other hypo-
thalamic peptides and neurotransmitters implicated as 
stimulators of prolactin secretion, are vasoactive intes-
tinal polypeptide (VIP), bombesin (134), substance P (135), 
neurotensin (136), endorphin (135,137) and enkephalins 
(138). As none of these sUbstances (with the exception of 
VIP) has been shown to exert a stimulatory action in vitro, 
the stimulatory effects of these substances are probably 
indirect via a hypothalamic action. VIP stimulates prolac-
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tin secretion after systemic administration (139) and has 
been found in hypophysial stalk blood (140). Reports of a 
prolactin-release stimulating effect are contradictory 
(139,141,142), although in one study the VIP concentration 
necessary to stimulate prolactin release in vitro was with-
in the physiologic range (142). Therefore, VIP is possibly 
a physiological PRF in addition to TRH. 
Serotonin. 
It appears that serotonin stimulates prolactin release in 
both rat and man (101, 143,144). In the rat no effect of 
serotonin on prolactin release has been found in vitro 
( 145). 
Inhibition of serotonin synthesis by parachlorophenylala-
nine blocks the prolactin peak following lactation in rats 
(146). From these and other studies (145,147)it seems 
reasonably certain that in rat and perhaps also in man 
serotonin influences prolactin release at a supra hypophy-
seal level, probably the hypothalamus. Research in this 
field has provided a lot of conflicting data using sero-
tonin antagonists. 
However the specificity of action of many of these com-
pounds remains doubtful (145). Thus Lamberts and McLeod 
(145) were able to show that methvsergide , a compound 
used as a serotonin antagonist in many studies, can act 
in different ways : as a serotonin antagonist, a dopamine 
agonist and a dopamine antagonist. 
Systemic injection of serotonin does not lead to PRL re-
lease, presumably because it cannot pass the blood brain 
barrier. Also, administration of the serotonin precursors 
L-tryptophan and 5-hydroxy-tryptophan (5-HTP) in humans 
led to conflicting results. Although some studies failed 
to find a modification of basal prolactin secretion by L-
tryptophan and 5- HTP given orally (148,149), others provi-
ded evidence that intravenous administration of L-trypto-
phan (150) and 5-HTP (151,152) does elevate plasma prolac-
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tin levels. It thus seems likely that the mode of admini-
stration influences the results. Although some influence 
of serotonin in human prolactin metabolism now seems cer-
tain, its relative importance as a PRF is still to be 
established. 
Estrogens. 
In 1909 Erdheim and Stumme (153) showed that the increase 
in pituitary weight during pregnancy, was entirely due to 
an increase of lactotropic cells. Later is was found that 
prolonged administration of estrogens led to pituitary 
enlargement (154) and to an increased mitotic rate of the 
lactotropic cells (104), while this effect could be 
blocked by the dopamine agonist bromocriptine. 
It has also been established that estrogens stimulate 
prolactin release in male and femakagonadal subjects (95, 
103) and elevate basal prolactin levels in normal menstru-
ating women (155), while the antiestrogen tamoxifen de-
creases plasma prolactin levels in normal women (156). In 
vitro, animal and human studies have provided evidence 
that estrogens significantly enhance the stimulating 
effect of TRH on prolactin secretion (101,157,158,170). 
This suggests that estrogens exert their effect in part 
via a direct influence on the receptor for TRH on the 
lactotropic cells. It was also shown that estradiol-17B 
has a direct effect on prolactin secretion in rat pituita-
ry cell cultures (159,160). Finally estradiol receptors 
have been found on rat pituitary lactotropic cells (161). 
All these findings support the proposition that estrogens 
influence prolactin release in part through a direct ef-
fect on the pituitary itself, perhaps through an estrogen 
induced reduction in the capacity to incorporate dopamine 
into prolactin secretory granules (168) or an estrogen 
induced reduction in the capacity of dopamine to stimu-
late lysosomal activity in the anterior pituitary gland 
(169). However, strong evidence also indicates an effect 
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of estrogens on prolactin release at a higher hypothalamic 
level (162,163). In rats the estrogen-induced prolactin 
rise can be blocked by bromocriptine administration (104), 
while incubation of rat anterior pituitary cells with es-
tradiol-17B leads to the reversal of the inhibitory ef-
fect of ergocornine, a dopamine agonist (105). Estrogens 
also induce a fall in hypophysial stalk plasma dopamine 
levels (164). An excessive rise of prolactin after TRH and 
ether stress in estradiol-primed rats has been described 
(165), probably as a result of a lowered dopamine secre-
tion from the hypothalamus (165,166,167). These findings 
suggest that the stimulation of PRL release by estrogens 
and the enhancement of the TRH-induced prolactin release 
by estrogens is effected by interference with the inhibi-
tory effect of hypothalamic dopamine. 
Conclusion: 
It appears that prolactin secretion is governed by many 
factors. A constant release of PIF normally prevents pro-
lactin release. This PIF is almost certainly dopamine; 
furthermore, mating, suckling and estrogens lead to a 
sustained prolactin release through a not completely un-
derstood mechanism although more and more evidence points 
to an effect at the hypothalamic level, probably through 
interference with the dopaminergic inhibition of prolac-
tin release. In contrast minor stress and also the admini-
stration of TRH lead to relatively small and short lived 
prolactin bursts, probably by overriding PIF by prolactin 
releasing factors, one of which may be TRH. 
DRUGS WHICH AFFECT PROLACTIN SECRETION. 
A great ~any drugs have been found to influence prolactin 
secretion in vivo, either positively or negatively (table 
I). In many instances the stimulation of prolactin relea-
se is effected by blocking dopamine action, interfering 
with catecholamine/dopamine synthesis or depletion of 
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catecholamine stores. 
Drugs which stimulate prolactin release. 
Phenothiazines. (chlorpromazine, perphenazine). 
Serum prolactin levels rise immediaelY after i.v. injec-
tion of perphenazine (171,172). This rise is caused by a 
blockade of ~he dopamine induced inhibition of prolactin 
release (110), either through an effect at the hypothala-
mic level (171,172), or directly on dopamine receptors at 
the pituitary gland (110). 
Butyrophenones (haloperidol, pimozide). 
Both haloperidol and pimozide block neurotransmission at 
dopaminergic receptors through competition with dopamine. 
It appears that the effect is dose related. In a low do-
sage both drugs stimulate prolactin release in vivo but 
not in vitro. In higher dosages the in vitro effect in-
creases (173). In still higher dosages both drugs seem to 
block the binding of dopamine or its receptor completely 
and start to function as dopamine agonists themselves ( 
173,174). 
Procaine derivates (sulpiride, metoclopramide). 
Sulpiride. 
When administrated intravenously sulpiride quickly leads 
to a sustained increase in serum prolactin levels (6), 
probably through a direct blocking effect on the activity 
of dopamine on the pituitary lactotropic cells (176). 
Metoclopramide. 
Metoclopramide is widely used as an antiemetic and peri-
sta~sisstimulating drug. Like sulpiride it leads to a 
prompt and sustained rise in prolactin levels (178) by a 
specific blocking effect on dopamine receptors in the 
pituitary gland (179,180). 
Antihypertensives (alpha methyldopa, reserpine). 
Alpha methyldopa administration leads to increased pro-
lactin levels by competitive inhibition of dopamine syn-
thesis at the hypothalamic level, while reserpine increa-
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ses prolactin levels indirectly through depletion of 
catecholamine stores in the central nervous system. 
Hormones and hormone antagonists. 
As has been discussed earlier thyreotropin releasing hor-
mone and estrogens both cause hyperprolactinemia through 
different mechanisms. The effect of sex steroids and 
their antagonists has also been investigated. The anties-
trogens lead, as can be expected, to a fall in prolactin 
levels and thus will be discussed later. It has been found 
that testosterone has no effect on prolatin release but 
its antagonist cyproterone acetate causes hyperprolactine-
mia in normal individuals (181) and in precocious puberty 
(182) through a still unclarified mechanism. 
Finally, chronic use of spironolactone (aldactone) can be 
associated with gynecomastia and elevated prolactin levels 
perhaps as a result of increased estrogen levels (183). 
Opiates. 
Morphine· (184) and brain opiates (185) stimulate prolactin 
release in man, while this effect can be blocked by the 
opiate receptor blocker naloxone (Narcan) ( 13 7,186) . It 
has been found that morphine acetate does not influence 
prolactin release_ by the pitu,taDy in vitro (187,188), thus 
suggesting an action at the hypothalamic level. The endo-
genous opioids B- endorphin, methionine-enkephaline and 
leucine-enkephaline have also been reported to elevate 
prolactin levels in rats (137,189). 
Despite reports to the contrary (190) endogenous opioids 
do not appear to influence prolactin release directly in 
vitro (137,187) and probably act at an higher CNS level. 
Histamine-2 receptor blocking agents (m~tiamide, cimetidi-
ne). 
Recently it has been found that metiamide (191) and cime-
tidine (192,193,194) significantly increase prolactin le-
vels in man. Although the mechanism of action is unknown 
it has been suggested that they may act through a blockade 
of brain H2 histamine receptors (194). In support of these 
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findings treatment with cimetidine can be accompanied by 
gynecomastia in a small percentage of patients (195). 
Drugs which inhibit prolactin release. 
Dopamine receptor stimulating drugs. 
L-Dopa. 
In rats with pituitary grafts, parenterally administered 
L-Dopa leads to a decrease in serum prolactin levels (196). 
The manner in which L-Dopa exhibits this effect is still 
a subject of controversy. L-Dopa may either inhibit pro-
lactin secretion through a direct effect on the pituitary 
(197,198) or through an effect on the pituitary after de-
carboxylation to dopamine (199). There is some evidence 
that L-Dopa inhibits prolactin release but not its synthe-
sis by the pituitary gland (200). Finally some reports 
haven·claimed that L-Dooa decreases serum prolactin levels 
by stimulating the uptake of the hormone in peripheral 
tissues (201,202). 
Ergot drugs. 
Although ergotamine itself (203) does not influence pro-
lactin levels other ergot derivates like ergocornine and 
ergocryptine do decrease prolactin levels significantly 
(203,204), by direct inhibition of prolactin release by 
the pituitary gland (205,206). This effect can be blocked 
completely by dopamine receptor blocking agents (207). 
The long-acting synthetic ergot derivate 2 bromo-alpha-
ergocryptine (bromocryptine) is so succesful in lowering 
prolactin levels that it has become the drug of choice in 
the treatment of hyperprolactinemia. 
In patients with prolactinoma s or functional hyperprolac-
tinemia, prolactin levels can be normalized in more than 
90% of cases by low doses (10 mg/24 hours) of bromocrip-
tine. The newer dopamine receptor agonists peribedil (208) 
lisuride (hydrogen maleate) (209) and lergotrile mesylate 
(210) all directly inhibit prolactin release through an 
effect at the dopamine receptor level in the pituitary 
approximately in the same way as bromocriptine. 
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Table I 
List of drugs known to influence prolactin release in vivo. 
Stimulators 
Neuroleptics 
Phenothiazines 
Butyrophenones 
Procaine derivatives 
l\1etoclopramide 
Sulpiride 
Antihypertensives 
x-methyl dopa 
reserpine 
Hormones and antagonists 
TRH 
Estrogens 
Cyproterone acetate 
aldosterone antagonists 
Opiates 
Morphine 
Brain opioids 
Others 
Cimetidine 
Metiamide 
Inhibitors 
L-Dopa 
Ergot drugs 
Bromocriptine 
Lergotrile 
Lisuride 
l\1etergoline 
Non Ergot drugs 
Apomorphine 
Peribedil 
Anti Estrogens 
Tamoxifen 
Clomifen 
Vit B6 (pyridoxine) 
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Non ergot drugs. 
Apomorphine. 
Apomorphine inhibits prolactin release in vivo and vitro 
directly at the pituitary level through dopamine receptor 
stimulation (211) in both normal controls and in patients 
with hyperprolactinemia (212). 
Antiestrogens (clomiphene, tamoxifen). 
The effect of Clomiphene, an estrogen receptor blocking 
agent, on prolactin release is unclear. Reports on a in-
hibit.ing effect of this drug on puerpueral lactation are 
contradictory (213,214,215). 
The nonsteroidal antiestrogen tamoxifen lowers basal but 
especially TRH stimulated prolactin levels in both animals 
(216,217) and man (156,218,219) and has been shown to 
inhibit lactation in puerperal women (219). The anties-
trogenic effect is exerted by competition at the estrogen 
receptor (220) and estrogen levels may even rise during 
administration (156). In rats an inhibiting effect of 
tamoxifen on pituitary tumor growth and prolactin synthe-
sis by the pituitary gland has been demonstrated (216,217), 
probably due to an inhibiting effect at the pituitary es-
trogen recentor (221). It has been shown in vitro in 
dispersed pituitary tumor cells that tamoxifen does not 
influence prolactin secretion directly but enhances the 
sensitivity of these cells to dopamine and to bromocrip-
tine (222). This enhancing effect can be prevented by 
coincubation with estradiol-17B. Tamoxifen in addition 
prevents the stimulatory effect of TRH on prolactin se-
cretion (222). 
PERIPHERAL METABOLISM OF PROLACTIN AND METABOLIC CLEARANCE. 
Studies with iodinated prolactin in animals (mainly rats) 
have shown specific binding of prolactin in many tissues 
including the ovary, mammary gland, uterus, kidney, liver, 
muscle, adrenal cortex, pituitary and brain (17,37,223, 
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224,225,226,227). 
Surprisingly the tissues showing the highest binding were 
the liver and the kidney (17,37,225,226). In the kidney 
radioactivity was concentrated in the proximal tubular 
epithelial cells (17,37,38,228), while in the liver radio-
activity was distributed diffusely throughout the liver 
lobule. Within the hepatocyte there appeared to be a spe-
cial preference for the Golgi apparatus (262). The liver 
receptors for prolactin were found to be separate from 
the reaptors for growth hormone (229). Both receptor bin-
ding and a significant clinical effect of Prolactin have 
been observed in the mammary gland, the ovary and the 
adrenals. The highest affinity for prolactin, however, has 
been found in the liver and the kidney, organs on which a 
clinical effect of prolactin is less obvious. 
However it does not follow automatically from these bin-
ding studies that prolactin exerts a specific effect on 
these tissues and it may merely indicate that both the 
liver and the kidney are important in prolactin degradation. 
However it does not seem likely that prolactin receptors 
sites in the liver are only associated with the degrada-
tion of the prolactin molecule (226,230), as prolactin 
may be involved in the synthesis of RNA (231), free fatty 
acids (232), somatomedin production (233) and maintenance 
of its own receptor levels (234). Finally, in contrast to 
growth hormone, no significant elimination by the liver 
of prolactin was found in normal men during hepatic vein 
catheterization studies (240). 
Prolactin receptors in the kidney have been studied less 
well. Prolactin seems to be concentrated in the proximal 
tubules. It appears that prolactin gains access to the 
epithelial cells via the glomerular filtrate (228). 
Although a specific action of prolactin on kidney metabo-
lism and osmoregulation has been claimed in man (41), the-
se results have not been confirmed (43,45,235,238); how-
ever, specific prolactin receptors in the kidney have 
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recently been described in the rat (38). 
The presence of specific binding sites for prolactin in 
the kidney again does not prove that the hormone has a 
physiological effect on osmoregulation and may merely 
indicate that the kidney is important for the clearance 
of prolactin.from the circulation, in the same way as has 
been shown for placental lactogen (236), parathormone 
(253), insuline, C Peptide (254), gastrin (255), glucagon 
(256) and vasopressine (257). Further support for this 
concept is provided by the fact that in renal disease, 
hyperprolactinemia only occurs when renal function is im-
paired and by the fact that the degree of increase in 
prolactin levels correlates directly with the degree of 
impairment of renal function (237,258), while prolactin 
levels can be normalized by transplantation (259). 
Chronic hemodialysis, however, does not seem to influence 
prolactin levels (260,261). Since only minute amounts of 
prolactin can be detected in the urine (239) even in pa-
tients with prolactinomas and very high serum prolactin 
levels Bauer et al, unpublished observations), it is 
probable that prolactin is broken down in the proximal 
tubular cells after resorption from the glomerular filtra-
te. 
Metabolic clearance rate. 
Ho~mone levels in the circulation are determined both by 
production and clearance rates. Usually metabolic clearan-
ce rates (MCR) are determined by the constant infusion to 
equilibrium technique (241). In this way the MCR of other 
polypeptides hormones like growth hormone (242,243), 
luteinizing hormone( 244), follicle stimulating hormone 
(245), thyrotropin (246) and gonadotropin releasing hor-
mone (247), have been determined. 
Because native human prolactin was not available in the 
past, studies of the metabolic clearance rate of prolactin 
in humans have only been performed recently. Using this 
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technique however, several studies in rats established 
MC rates in that animal (248,249,250,251).Kock et al 
(248) found no difference in MCR in male and female rats. 
They also did not find an influence of ovariectomy, hypo-
physectomy, or the stage of the estrous cycle on the MCR 
of prolactin. These findings were later confirmed by 
Jacobi and Lloyd in male rats (249). Grosvenor and 
Whitworth (250) also did not observe a difference in MCR 
between lactating and nonlactating animals. The same 
authors described an increase of the metabolic clearance 
of prolactin when the infusion rate was increased (251), 
suggesting an ability to clear greater amounts of prolac-
tin as the plasma concentration increases. In 1979 Cooper 
et al (252) finally described the MCR of prolactin in hu-
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mans. The MCR in women was 45 + 1 ml/min per m and 44 
± 3 ml/m2 in men, and was highly correlated with body mass. 
They also found that the MCR was slightly lower in the 
hyperprolactinemic patients (40 ± 5 ml/min per m2 ) and 
that dopamine infusion did not substantially alter the 
prolactin MCR. 
PRL production rates (PR) were not significantly differenL 
2 in males and females (187 + 44 ugjday per m , and 211 ± 
74 ug/day per m2 respectively) while the PR was extremely 
high in hyperprolactinemia due to prolactinoma (PR = 
2 31.000 ± 29.000 ug/day perm, n = 9). Dopamine infusion 
decreased prolactin PR from 270 to 66 ug/day per m2 , which 
indicates that its effect is on secretion rather than 
clearance. 
HYPERPROLACTINEMIA. 
l!yperprolactinemia may be one of the most common endocrine 
disorders in clinical practice. In unselected patients 
with secondary amenorrhea the incidence of hyperprolacti-
nemia is between 13 and 20% (263,264,265). Similar figures 
have been reported on the incidence of hyperprolactinemia 
in anovulatory syndromes (264,265,266,267,268). Patients 
may present with such diverse symptoms as visual field 
defects, headaches, amenorrhea, uterine bleeding, galac-
torrhea, infertility with or without amenorrhea and impo-
tence and may thus be seen by specialists in many non-
endocrine fields. 
Clinical presentation in the female. 
The clinical presentation of hyperprolactinemia in the 
female is related to the disturbed hypothalamic pituitary 
gonadal axis, with irregular menstruation, short luteal 
phase, anovulation, or amenorrhea as the presenting symp-
toms. As mentioned earlier, the incidence of hyperprolac-
tinemia in amenorrheic and anovulatory syndromes may be 
in the order of 20%. In these patients ovulation and 
menstruation may be restored by treatment with the prolac-
tin secretion inhibiting drug bromocriptine (269). The 
next common clinical feature of hyperpro:Lactinemia is ga-
lactorrhea,either spontaneous or only on breast pressure 
(270,271). Galactorrhea has been found in up to 40% in 
patients with hyperprolactinemia (263,265). 
Clinical presentation in the male. 
Impotence, decreased libido, infertility, galactorrhea and 
delayed puberty may be the presenting symptoms in male pa-
tients with hyperprolactinemia. Elevated serum PRL levels 
were found in 17% of patients with impotence (272), while 
Thorner et al found impotence in allmost all Dyperprolac-
tinemic men studied by them (273). 
In the former study the beneficial effect of bromocriptine 
treatment was not higher than that of placebo.In long 
standing hyperprolactinemia plasma testosterone levels 
may be suppressed (273,274), while the serum PRL levels 
in a large group of infertile men were found to be signi-
ficantly higher than in infertile controls (275). In this 
study hyperprolactinemia was found to interfere with sper-
matogenesis. Others have reported normalization of sperma-
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togenesis after bromocriptine treatment (276).Finally, 
Thorner et al reported galactorrhea in one third of men 
with hyperprolactinemia (273), but gynaecomastia was less 
frequent. 
Causes of hyperprolactinemia. 
Increased serum PRL levels are found in a number of cli-
nical conditions (table n) . The most common causes are the 
use of psychotropic and anti-hypertensive drugs as discus-
sed earlier and pituitary (micro) adenomas, either 
through autonomous prolactin secretion or pressure of an 
upward growing tumor on the pituitary stalk. Infiltrative 
processes of the hypothalamus also may lead to hyperpro-
lactinemia through interference with the hypothalamic-
hypophyseal portal circulation and thus to disruption of 
the tonic inhibition of prolactin secretion. Primary hypo-
thyroidism may also cause hyperprolactinemia (277), which 
can be normalized by treatment with thyroxine (267). When 
prolactin levels do not return to normal after thyroxine 
treatment a concomittant PRL secreting pituitary adenoma 
should be suspected. However, since abnormalities of the 
sella may regress under a thyroxine treatment, the diag-
nosis of such a tumor may be difficult (278,279,280). 
The hyperprolactinemia in chronic renal disease and in 
chronic liver disease will be discussed in separate chap-
ters. 
29 
Table II 
Causes of elevated serum PRL concentrations. 
- prolactin secreting pituitary tumors 
- non-prolactinomas pressing upon the pituitary stalk 
- infiltrative processes in the hypothalamus 
- histiocytosis, sarcoidosis 
metastatic tumors, leukemia 
- target endocrine gland failure 
- hypothyroidism 
- hypoadrenalism 
polycystic ovarian syndrome 
- chronic renal failure 
- chronic liver failure 
- drugs 
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Hyperprolactinemia and chronic renal disease. 
The kidney may be an important clearing organ for prolac-
tin (237). In patients without renal disease a 16% trans-
renal arterio-venous prolactin concentration difference 
was established. It is thereforenot surprising that seve-
ral studies reported the occurence of hyperprolactinemia 
in chronic renal disease (95,237,238,259,260,281). Further-
more a significant relationship between plasma creatinine 
and prolactin concentrations was found (237), while ele-
vated prolactin levels return to normal after kidney trans-
plantation (259). 
Hemodyalisis does not influence prolactin levels (238, 
261) and a disturbance of prolactin secretion may also 
exist (259,282,283), in view of the fact that in chronic 
renal disease both the responsiveness to TRH stmulation 
as well as the suppression by L-dopa and dopamine infu-
sions is diminished (258,259,261,283). 
Hyperprolactinemia and chronic liver disease. 
After a report that the number of prolactin secreting 
cells in the anterior pituitary was increased in approxi-
mately a half of patients (286) with Laennec-s cirrhosis, 
several studies reported elevated prolactin levels in 
this condition (287,288,289,290,291,292,293,294). 
The hyperprolactinemia is usually moderate (290,291,292) 
and in fact plasma prolactin levels may be normal (292, 
295,296,297,298,299,300). On the other hand many, although 
not all, studies report exaggerated prolactin responses 
to TRH (289,290,291,292,294,300,301). The interpretation 
of these contrasting findings is further complicated by 
the fact that several drugs, often prescribed in such pa-
tients, are able to stimulate prolactin release. Several 
reports do not differentiate between alcoholic cirrhosis 
and alcoholism per se (288) or between alcoholic and non-
alcoholic liver cirrhosis (290). Both elevated (302,303) 
and normal (304) plasma prolactin levels have been des-
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cribed after acute and chronic alcohol intake. Some au-
thors report higher plasma prolactin concentrations in 
alcoholic liver cirrhosis compared to liver cirrhosis of 
other etiology (291); these differences are more prominent 
after TRH stimulation (289,291,294,300). ~1organ et al (292) 
however did not find a statistically significant differen-
be between plasma prolactin levels in alcoholic and non-
alcoholic liver cirrhosis. Generally prolactin levels seem 
to be higher in relation to the enent of the liver paren-
chymal damage, although this is not invariably so. Morgan 
et al (292) found hyperprolactinemia in 4% of patients 
with alcoholic steatosis and in 16% of patients with alco-
holic hepatitis and cirrhosis. Wernze et al (291) found 
hyperprolactinemia in 27% of patients with cirrhosis with-
out ascites but in 47% of patients with ascites, while 
van Thiel et al (293) found a tendency towards a relation-
ship between liver function parameters and basal plasma 
prolactin levels. Langer et al (301) found higher plasma 
prolactin concentrations in decompensated liver disease 
than in compensated liver disease, while the response to 
TRH was significantly increased. Others, however, failed 
to find a direct relationship between liver function 
parameters and circulating prolactin levels (292,294). 
Serum prolactin concentrations are higher in cirrhotic 
patients with hepatic encephalopathy (305) compared to 
cirrhosis without encephalopathy and they are also found 
to be elevated in the hepatic encephalopathy of Reye-s 
syndrome (306). The relationship between hyperprolactinc-
mia, liver cirrhosis and gynecomastia is also controver-
sial. Some studies report a direct relationship between 
plasma prolactin levels and gynecomastia (288,289); others 
however, could not confirm these results (291,292,296). 
Certainly not all patients with gynecomastia have elevated 
prolactin levels (292) nor do all patients with hyperpro-
lactinemia develop gynecomastia. It seems likely therefore 
that hyperprolactinemia plays a role in the 
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development of gynecomastia only in cooperation with other 
factors, such as a disturbed estrogen/testosterone balance, 
which has been found to correlate positively with gyne-
comastia in chronic liver disease (307,308,309). It is in-
teresting in this respect that a disturbed estrogen/tes-
tosterone balance with increased estrogen levels and de-
creased testosterone levels has been found to increase PRL 
receptor activity (284,285). The role of prolactin in gona-
dal insufficiency occurring in liver cirrhosis is also not 
clear. Hyperprolactinemia leads to hypo or amenorrhea and 
libido disturbancies irrespective of gonadotropin secre-
tion (310), while long-term hyperprolactinemia leads to a 
decrease of plasma testosterone levels (311). 
In conclusion, plasma prolactin levels may be mildly ele-
vated in liver cirrhosis and often show an exaggerated 
response after TRH stimulation. Hyperprolactinemia seems 
to be correlated with the severity of liver parenchymal 
function loss and is especially notable in patients with 
cirrhosis and ascites and in patients with hepatic ence-
phalopathy. Hyperprolactinemia occurs more readily in al-
coholic cirrhosis than in other forms and can be caused 
by alcoholism alone. Although possibly a factor in the 
development of gynecomastia and hypogonadism of liver 
cirrhosis, its exact role remains unclear. 
The mechanism of hyperprolactinemia in liver cirrhosis. 
Elevated hormone levels may be caused by a decreased 
metabolic rate, and increased secretion rate or both. 
Very little is known about the metabolic clearance rate 
of prolactin in liver cirrhosis. However, the kidney seems 
to be important in prolactin clearance (237) while in nor-
mal man no hepatic extraction of prolactin is found (240); 
This suggests that liver disease may not greatly affect 
prolactin clearance. Also, the exaggerated rise of prolac-
tin after TRH and the loss of the diurnal changes in plas-
ma prolactin levels (213) primarily indicate an abnormali-
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ty in the control of prolactin secretion. Prolactin secre-
tion is mainly regulated by tonic hypothalamic inhibition 
through dopamine and seems to be further subject to the 
stimulatory influences of hypothalamic releasing factors 
and estrogens. Circulating estrogens are elevated in liver 
cirrhosis both through an increased peripheral aromati-
zation of testosterone via androstenedione (309,314,315) 
and to a lesser extent through a decreased elimination 
by the liver (316). As estrogens stimulate prolactin re-
lease both through interference with dopamine from the 
hypothalamus, and through a direct effect on the anterior 
pituitary (103,104,105,313), it is possi~ that hyperpro-
lactinemia in liver cirrhosis is caused by elevated estro-
gen levels. On the other hand, the increased prolactin 
levels may be caused by a disturbance of the hypothalamic 
inhibitory and stimulating factors. It is interesting in 
this respect that plasma prolactin concentrations are more 
elevated in cirrhosis with hepatic encephalopathy. In this 
condition changes in amino acid balance may lead to chan-
ges in central neurotransmitter systems. 
Several authors have suggested that in hepatic encephalo-
pathy false neurotransmitters (e.g.octopamine instead of 
dopamine) might be formed due to a change in the ratio 
of plasma aromatic amino acids to branched chain amino 
acids (317,318). This theory is based on evidence that in 
hepatic encephalopathy aromatic amino acids (e.g. trypto-
phan and tyrosine) are increased in relation to the 
branched chain amino acids. As these amino acids all com-
pete for the same carrier through the blood-brain barrier 
(319), this will result in an excess of aromatic amino 
acid/neuro transmitter precursors in the brain. Because 
tyrosine is the precursor for catecholamine synthesis and 
tryptophan the precursor for serotonin synthesis these 
changes are expected to influence neurotransmitter levels 
substantially. It appears that excess tyrosine in the 
brain cannot be handled in the normal way because of rate 
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limiting enzymes, and octopamine is formed instead of do-
pamine (317). On the other hand elevated levels of 5-
hydroxyindole acids in the cerebrospinal fluid indicate 
an increased production and turnover of serotonin (320,321) 
A relationship has been established in liver cirrhosis 
between free plasma tryptophan levels and prolactin le-
vels (290). It is therefore likely that both decreased 
dopamine levels and/or increased serotonin levels play 
a role in the hyperprolactinemia of liver cirrhosis, es-
pecially in hepatic encephalopathy. This is further sub-
stantiated by the fact that the administration of both 
the dopamine agonists bromocriptine (322) and L-dopa 
(323) have. been found to result in a dramatic clinical 
improvement of hepatic encephalopathy, with disappearance 
of coma. 
In conclusion, although not much is known about the meta-
bolic clearance rate of prolactin in liver cirrhosis, it 
is expected that the MCR will not be greatly affected in 
liver cirrhosis. On the other hand the regulation of pro-
lactin secretion seems to be disrupted, probably through 
the combined effect of increased estrogen levels, increa-
sed hypothalamic serotonin levels and decreased hypothala-
mic dopamine levels. 
This present study was undertaken to bring more clarity 
in the mechanism of hyperprolactinemia in chronic liver 
disease. In order to do this we formulated the following 
5 questions. 
1. what is the relative importance of the liver in the 
elimination/degradation of prolactin in liver disease 
and is prolactin degradation decreased in chronic liver 
disease. 
2. Is prolactin degradation in chronic liver disease dif-
ferent from that of hormones of comparable molecular 
weight. 
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3. Is there evidence of a disturbance of central prolactin 
release and if so what is the relative importance of 
increased estrogens and/or impaired dopamine inhibi-
tion. 
4. Is the hyperprolactinemia of liver cirrhosis caused by 
the decreased parenchymal function or by the concomit-
tant portal hypertension with porto-systemic shunting? 
5. Is the hyperprolactinemia of compensated liver cirrho-
sis caused by factor-s different from those that cause 
the prolactinemia of hepatic encephalopathy ? 
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CHAPTER 3 
THE KIDNEY IS THE MAIN SITE OF PROLACTIN ELIMINATION IN 
PATIENTS WITH LIVER DISEASE. 
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The Kidney is the Main Site of Prolactin Elimination in 
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ABSTRACT. Basal and TRH-stimulated PRL!evels have been 
reported to be increased in patients with severe liver disease. To 
elucidate the relative role of the liver and kidney in the elimi-
nation of PRL in such patients. plasma PRL levels were meas-
ured before and after TRH in peripheral, hepatic, and renal vein 
samples taken from eight patients undergoing diagnostic hepatic 
vein catheterization. In two patients, arterial PRL levels, effec-
tive renal plasma flow, and estimated hepatic plasma flow were 
measured. All patients had evidence of portal hypertension with 
parenchymal liver cell insufficiency varying from mild to severe. 
There was no significant difference among basal arterial. periph-
eral, hepatic, and renal venous PRL levels. After TRH admin-
istration, the mean renal PRL levels were significantly lower 
than the mean peripheral levels in six of eight individual patients 
and lower when mean renal venous PRL levels and mean pe-
ripheral levels of all patients taken together were compared (P 
< 0.001). The two patients in whom no significant difference was 
A LTHOUGH current knowledge of PRL secretion and metabolism is steadily increasing, relatively 
little is known about PRL elimination. Recent reports 
(1-3) show elevated plasma PRL levels in patients with 
either liver or kidney failure. To elucidate the relative 
role of the liver and kidney in the elimination of PRL in 
patients with liver disease, we measured plasma PRL 
levels before and after TRH injection in peripheral, he-
patic, and renal vein samples taken from patients un-
dergoing diagnostic hepatic vein catheterization. 
Materials and Methods 
Eight consecutive patients with liver disease with evidence 
of portal hypertension in whom wedged hepatic vein pressure 
measurements were indicated were asked to participate. The 
clinical and laboratory findings are shown in Table L The 
diagnosis ofliver disease was based on percutaneous liver biopsy 
and laparoscopy in all instances. The function of the liver 
parenchyma, as measured by plasma albumin, Thrombotest 
(Nyegaard, Oslo, Norway), Normotest (Nyegaard), and biliru-
bin determination, ranged from normal to severely disturbed 
(Table 1). Renal function was monitored by plasma creatinine. 
Received August 22, 1979. 
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found were the only patients who also had evidence of disturbed 
kidney function. Mean hepatic venous levels after TRH stimu-
lation were slightly lower than mean peripheral levels, although 
the difference was significant in only one patient. The difference 
between mean hepatic and peripheral venous PRL levels of all 
patients taken together was also significant (P < 0.025). In two 
patients, effective renal plasma flow measured 468 and 324 ml( 
min, respectively. and estimated hepatic plasma flow measured 
657 and 815 ml/min. From these data renal extraction of PRL 
was calculated to be 186.0 and 94.0 p.g during the 60 min, while 
liver extraction of PRL amounted to only 16.4 and 11.4 flg, 
respectively. 
The finding that hepatic elimination was not markedly af-
fected by the severity of liver disease suggests that the kidney is 
more important than the liver in the removal of PRL. In patients 
with liver disease the kidney is the main site of PRL elimination. 
(J Clin Endocrinol Metab 51: 70, 1980) 
Wedged hepatic vein pressure measurements were performed 
by the Seldinger technique via the femoral vein. This procedure 
was followed by iv injection of 400 p.g TRH (Relefact, Hoechst, 
Amsterdam, The Netherlands). At 0, 10, 20, 30, 40, 50, and 60 
min, blood samples were drawn selectively from the cubital, 
renal, and hepatic veins, while in patients 7 and 8 samples were 
taken from an indwelling needle in the radial artery at the same 
time. The renal and hepatic venous samples were taken by 
means of single catheter which was rapidly moved between the 
two veins. Samples were taken within 90 sec of of each other. 
All samples were immediately centrifuged, and the plasma was 
stored at -20 C until assay. Duplicate PRL levels were meas-
ured by immunoassay (normal value, up to 12 ng/ml in males 
and up to 15 ng/ml in females). The intraassay variation of 
determinations was 4.5% (50 duplicates; 2-50 ng/ml), and the 
interassay variation was 3.8% (mean, 14 ng/ml; n = 12). In 
patients 7 and 8, estimated hepatic plasma flow and effective 
renal plasma floW measurements were made at the same time 
during hepatic and renal vein catheterization. Estimated he-
patic plasma' flow was measured by continuous infusion of 
indocyanine green (4); effective renal plasma flow was measured 
by continuous infusion of C"1I]hippuran (5). Renal and hepatic 
removals of PRL in these two patients were calculated during 
the 60 min after TRH by the following equation, assuming a 
constant hepatic and renal plasma flow during the procedure: 
renal PR1 removal = (1\ - R) X ERPF X 60 and hepatic PRL 
removal = (A - H) x EHPF x 60, where A is the mean arterial 
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TABLE 1. Clinical particulars and laboratory results of the eight patients undergoing catheterization 
Patient no. 2 3 4 8 
Incomplete Macronodular Idiopathic Hepatic Alcoholic cir- Steatosis he- cirrhosis+ Alcoholic Alcoholic cir-Pathology 
rhosis patis septal fibro- chronic active hepatitis rhosis portal hyper- schistosomi-
sis tension asis 
Age (yr) 44 67 68 
Sex M F M 
BW(kg) 67 62 68 
Clinical portal hyper- + ± + 
tension 
Wedged HVP-free 17 19 
HVP (mmHg) 
Bilirubin (mg/dl) 9.4 3.0 1.2 
Normotest (%) 19 140 73 
Thrombotest (%) 16 85 
Albumin (g/liter) 28 32.6 45 
Creatinine (mg/dl) 1.2 0.5 1.1 
HVP. Hepatic vein pressure. 
PRL level, R is the mean renal venous PRL level, H is the 
mean hepatic venous PRL level, ERPF is the effective renal 
plasma flow, and EHPF is the estimated hepatic plasma flow. 
Statistical analysis 
The statistical significance of peripheral-renal vein and pe-
ripheral-hepatic vein differences was assessed by Student's 
paired t test. Both in the group as a whole and in each individual 
patient, all of the post-TRH PRL values (at all time points) 
were considered together in calculating the statistics. 
Results 
There was no significant difference among basal pe-
ripheral, renal, and hepatic venous PRL levels in the 
eight patients. After TRH stimulation, the mean renal 
venous PRL levels in each individual were significantly 
lower than mean peripheral PRL levels in six of the eight 
patients (Figs. 1 and 2 and Table 2; "patients 1, 2, and 7, 
P < 0.01; patient 5, P < 0.005; patients 3 and 4, P < 
0.001). In patient 8, the difference was not significant. 
This patient had a slightly elevated serum creatine level, 
while the effective renal plasma flow was below normal. 
Patient 6 (Fig. 3) showed a different pattern, with a 
delayed progressive rise of PRL after TRH and no sig-
nificant difference among the peripheral, renal, and he-
patic venous levels. This patient had severely disturbed 
kidney function due to chronic glomerulonephritis in 
addition to his liver disease. The difference between 
mean peripheral and mean renal venous levels of all 
patients taken together was highly significant (P < 
0.001). Mean hepatic venous PRL levels were signifi-
cantly lower than peripheral levels in only one patient 
(patient 5; P < 0.05); however, when the hepatic and 
peripheral venous values of all patients were combined, 
the difference between mean hepatic and peripheral lev-
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FIG. 1. Peripheral, hepatic, and renal venous PRL levels before and 
after TRH in patient 2. 
els was significant (P < 0.025). 
In patients 7 and 8, arterial and peripheral venous 
levels were not found to differ significantly. The mean 
post TRH difference in PRL levels between hepatic vein 
and peripheral vein and between renal vein and periph-
eral vein did not correlate with the severity of liver 
failure, as judged by the albumin and clotting factor 
levels. In patients 7 and 8, effective renal plasma flows of 
468 and 324 ml/min, respectively, were calculated assum-
ing constant renal plasma flow during the duration of the 
catheterization. PRL levels of 186 and 94 JLg, respectively, 
were determined to have been extracted by the kidney. 
In the same patients, estimated hepatic plasma flow rates 
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TABLE 2. PRL levels (nanograms per ml) before and after TRH in 
peripheral, hepatic, and renal vein samples (mean ± SEM) 
Time (min) 
10 20 30 40 50 60 
Peripheral vein 
Mean 7.7 46.8 49.8 48.6 44.8 39.9 33.2 
SEM 1.3 6.5 6.5 6.4 4.6 5.1 5.1 
Hepatic vein 
Mean 7.6 43.2 52.0 45.2 41.6 38.1 33.4 
SEM 2.3 4.9 6.8 6.2 5.9 4.9 4.2 
Renal vein 
Mean 7.1 40.4 44.9 41.1 37.7 34.3 29.5 
SEM LO 4.9 5.8 5.3 4.6 4.8 5.2 
of 657 and 815 rnl/min were found. Assuming a constant 
hepatic plasma flow, 16.4 and 11.4 p.g PRL, respectively, 
were calculated to have been extracted by the liver during 
the same 60-min period. 
Discussion 
The organs involved in the inactivation of PRL have 
been studied in several animal species. Raganiemi et al. 
(6) observed a rapid accumulation ofiv administered 1251-
labeled ovine PRL in the livers and kidneys of both mice 
and rats. With microautoradiography of the liver, a dif-
fuse distribution of C2'I]PRL in the liver suggested that 
both the parenchymal and Kuppfer cells may be involved 
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FIG. 3. Peripheral, hepatic. and renal venous PRL levels before and 
after TRH in a patient with cirrhosis arid chronic glomerulonephritis 
(patient 6). 
in the inactivation of PRL. In the kidney, PRL was 
almost exclusively localized in the proximal tubular cells. 
Donatsch and Richardson (7) confirmed, with a fluores-
cein-labeled double antibody technique, that 30 sec after 
iv injection, the ovine PRL could be visualized in the 
lumina of the proximal tubular; these findings suggested 
that the hormone gained access to these cells via the 
glomerular filtrate. 
Cowden et al. (3) found elevated PRL levels in 32% of 
patients with renal disease. A significant correlation was 
observed between PRL and creatine concentration in 
these patients, while PRL reverted toward normal after 
successful renal transplantation. A significant arterioven-
ous PRL concentration difference across the kidney was 
found under basal conditions in seven patients with non-
renal, nonendocrine disease, suggesting that the kidney 
plays an important role in PRL metabolism. 
In contrast, Modiinger and Gutkin (8) reported that 
the mean renal venous PRL concentration did not differ 
from peripheral venous concentrations obtained simul-
taneously during renal vein catheterization. TRH stim-
ulation, however, was not used. 
Lim et al. (2) observed a diminished responsiveness to 
TRH in chronic renal failure. In these patients the PRL 
response was less than that in controls, and the time of 
response was delayed 30 min. Panerai et al. (1), on the 
other hand, found an exaggerated and sustained PRL 
rise after TRH stimulation in subjects with liver disease 
whose mean basal plasma PRL levels were within normal 
range. 
In our study no difference was found in basal periph-
n 
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eral, hepatic, and renal venous PRL levels. After TRH 
stimulation, however, significantly lower PRL levels were 
found in the renal vein compared with peripheral PRL 
levels in six of eight patients, while the difference between 
renal and peripheral levels of PRL in all patients taken 
together was also highly significant. The two patients in 
whom no significant difference was found were the only 
patients who also had impaired renal function. Patient 8, 
in whom the difference was not significant, had a slightly 
elevated serum creatinine level and a diminished effec-
tive renal plasma flow. Patient 6 had severely disturbed 
renal function due to chronic glomerulonephritis. In this 
patient, the reaction to TRH stimulation was of the type 
described by Lim (2) in chronic renal failure. Hepatic 
vein PRL levels were somewhat lower than peripheral 
levels in seven of eight patients, although this difference 
reached significance in only one patient (patient 5). How-
ever, when the hepatic and peripheral venous PRL levels 
of all patients taken together were compared, the differ-
ence was found to be statistically significant (P < 0.025). 
In two patients, renal extraction of PRL was found to 
be 186 and 94 p.g, respectively during a 60-min period 
compared to a liver extraction of 16.4 and 11.4 p.g, re-
spectively, during the same 60-min period. These results 
suggest that the kidney is the main site of PRL elimina-
tion in patients with hepatic disease, while the liver plays 
only a minor role. For obvious reasons, a control group 
could not be established. However, the fact that there 
was no relation between hepatic elimination of PRL and 
degree of liver failure suggests that even in the presence 
of normal hepatic function, the kidney is more important 
than the liver in PRL elimination. This point is further 
substantiated by a recent report by Bratusch-Marrain et 
al. (9), who did not find a significant uptake of endoge-
nous PRL by the liver in 12 healthy patients. The mech-
78 
anism by which PRL is removed by the kidney is not 
clear. In view of the molecular weight of PRL, it is likely 
that it passes into the glomerular filnate. Since only a 
small amount has been detected in the urine (10) most of 
the PRL is probably taken up by the tubular cei!s. 
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ABSTRACT. 
Chronic liver disease is associated with raised basal and 
TRH stimulated PRL and GH levels. In a recent study we 
found the kidney to be the main site of prolactin elimina-
tion in patients with liver disease. In order to determine 
whether this is specific for PRL or a more general mecha-
nism for polypeptide removal we studied the elimination 
of GH, which resembles PRL in molecular weight and primary 
amino acid sequence, in 5 patients with portal hyperten-
sion and hepatic cirrhosis and 5 patients with non-cirrho-
tic portal hypertension. Plasma GH levels were measured 
before and after TRH in peripheral, hepatic and renal 
vein samples, taken during diagnostic hepatic vein 
catheterization. An excessive paradoxical increase of GH 
after TRH stimulation was found in 4 out of 5 cirrhotic 
patients but in none of the noncirrhotic individuals 
(p < 0.025). After TRH the mean hepatic venous levels were 
significantly lower than the peripheral venous levels in 
4 out of 5 noncirrhotic patients but in only one of the 5 
cirrhotic patients ( p ~ 0.05). The mean renal vein GH 
levels were significantly lower than the peripheral levels 
in 3 out of 5 noncirrhotic patients and in none of the 
cirrhotic patients. In two patients in whom renal and 
hepatic plasma flow was measured, renal extraction of GH 
was found to be 0 ug and 6.4 ug, while liver extraction 
amounted to 22.1 ug and 34.7 ug of GH during the same 60 
minute period. Despite the similarity in molecular weight 
and primary amino acid sequence between PRL and GH, GH 
appears to be mainly taken up by the liver while PRL is 
mainly eliminated by the kidney in this group of patients 
with portal hypertension. This suggests that the renal 
elimination of prolactin is not solely dependent on glome-
rular filtration. The selective hepatic removal of growth 
hormone is probably related to a specific action of growth 
hormone on liver metabolism. 
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INTRODUCTION. 
Chronic liver disease is associated with raised basal and 
TRH stimulated levels of prolactin (PRL) and growth hor-
mone (GH) (Panerai et al 1977). In a recent study we 
showed that the kidney was the main site of PRL elimination 
in patients with liver disease (Bauer et al 1980). It has 
been suggested that due to its molecular size, PRL passes 
into the glomerular filtrate and is then either taken up 
by the tubular cells or excreted in the urine (Nader et al 
1975). In view of the resemblances in molecular weight and 
primary amino acid sequence between PRL ( Shome and Parlow 
1977) and GH (Niall et al 1973) we measured GH in plasma 
from peripheral, renal and hepatic veins from the same 
patients, to determine whether GH elimination occurs in a 
similar fashion to PRL elimination. 
PATIENTS,MATERIALS AND HETHODS. 
Ten consecutive patients with clinical portal hypertension 
in whom wedged hepatic vein pressure measurements were 
indicated, were asked to participate. All patients had 
splenomegaly and presented with varying degrees of oeso-
phagal varices and/or ascites. 
Clinical and laboratory findings are summarized in table I. 
The patients could be subdivided into a group of five pa-
tients with histologically proven liver cirrhosis and a 
group of five patients with noncirrhotic portal hyperten-
sion. The diagnosis of liver disease was confirmed by 
percutaneous liver biopsy and laparoscopy in all instances. 
Liver parenchymal function, as assessed by plasma albumin, 
R R Thrombotest ( Nyegaard, Oslo,Norway), Normotest (Nyegaard) 
and bilirubin determination, ranged from normal to severely 
disturbed (table I). Renal function was monitored by plasma 
creatinine. Wedged hepatic vein pressure measurements were 
performed by the Seldinger technique via the femoral vein. 
81 
Heparinised blood samples from hepatic, renal and ante-
cubital veins before and at 10 minute intervals during 
one hour after the intravenous injection of 400 ug of TRH 
(Relefact R, Hoechst) were taken. The renal and hepatic 
venous samples were taken by means of a single catheter 
which was rapidly moved between the two veins. Samples 
were taken within 90 seconds of each other. In patients 
7 and 8 arterial samples were obtained from an indwelling 
needle in the radial artery, and in addition estimated 
hepatic plasma flow and effective renal plasma flow 
measurements were made at the same time during hepatic 
and renal vein catheterization. Estimated hepatic plasma 
flow was measured by continuous infusion of Indocyanine 
Green (Leevy et al 1962); effective renal plasma flow was 
measured by continuous infusion of c131 r) Hippuran (Danker 
et al 1977). 
Renal and hepatic GH removal during the catheterization in 
patients 7 and 8 were calculated as follows: 
Renal GH removal = ( A - R x ERPF x 60 
Hepatic GH removal =( A H x EHPF x 60 
where A = mean arterial GH, R mean renal vein GH, H = 
mean hepatic vein GH, ERPF = effective renal plasma flow 
and EHPF = estimated hepatic plasma flow. 
Duplicate GH levels were measured by immunoassay (I.R.E.). 
Normal values under basal conditions are less than 5 ng/ml; 
the interassay variation of determinations was 5.3% (30 
duplicates 1-25 ng/ml) and the interassay variation was 
4.2% (x = 3.8 ng/ml; n = 8). 
Statistical analysis: The statistical significance of 
differerices in peripheral and renal vein, and peripheral 
and hepatic vein GH levels, was assessed by paired Stu-
dent s t-test. In each individual patient and in the 
patient groups all of the post-TRH GH values were used in 
the analysis. 
The significance of differences between the two patients 
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groups in the incidence of paradoxical GH increases after 
TRH and the occurence of significant peripheral - renal 
vein and significant peripheral - hepatic vein differences, 
was assessed by Fishers exact probability test. 
RESULTS. 
There was no significant difference between basal periphe-
ral, renal and hepatic venous GH levels in the 10 patients, 
nor were there significant differences in the basal GH 
levels between the cirrhotic and the noncirrhotic group 
(table II). An excessive increase in GH after TRH stimu-
lation was found in 4 out of 5 cirrhotic patients but in 
none of the noncirrhotic individuals ( p < 0.025). The 
paradoxical increase of GH after TRH did not however 
correlate with serum albumin, a decrease in clotting fac-
tors as measured by the Normotest R, bilirubin or SGOT 
concentration, nor with renal function as measured by the 
serum creatinine level. After TRH stimulation the mean 
hepatic vein levels were significantly lower than the 
peripheral venous levels in 4 out of 5 noncirrhotic pa-
tients, but in only one of the 5 cirrhotic patients 
(p < 0.05). The mean renal vein GH levels were signifi-
cantly lower than the peripheral levels, in 3 out of 5 non-
cirrhotic patients and in none of the cirrhotic patients. 
Examples of growth hormone levels in the renal, hepatic 
and peripheral veins from patients from each group are 
shown in fig. 1 and 2. The difference between all hepatic 
vein and all peripheral vein GH levels of each group when 
taken together was found to be statistically significant 
( p < 0.001). The difference between all renal vein and 
all peripheral vein GH levels was also significant for 
both groups when all individuals were taken together(cir-
rhotic group p < 0.05, noncirrhotic group p < 0.001). 
Mean values for all peripheral vein GH levels were 13.8 
ng/ml for the cirrhotic patients and 4.2 ng/ml for the 
noncirrhotic group, mean values for all hepatic vein GH 
levels were 12.9 ng/ml for the cirrhotics and 3.1 ng/ml 
for the non-cirrhotics; mean renal vein GH levels were 
12.9 ng/ml and 3.6 ng/ml for the two groups. 
In patients 7 and 8 arterial and peripheral vein levels 
did not diff.er significantly. In patient 7 renal extrac-
tion of GH could not be demonstrated. In patient 8 the 
difference in peripheral and renal vein GH levels was 
significant p ( 0.05). This patient had a renal plasma 
flow of 324 ml/min and assuming a constant renal plasma 
flow during the duration of the catheterization it was 
calculated that 6.4 ug of GH was extracted by the kidneys 
in this patient. In the same patients an estimated hepatic 
plasma flow of 657 ml/min and 815 ml/min was found. Again 
assuming a constant hepatic plasma flow it was calculated 
that 22.1 ug and 34.7 ug of GH were extracted by the 
liver during the same 60 minute period. 
DISCUSSION 
Both the liver and the kidney have been implicated in the 
peripheral elimination of GH, and it has been suggested 
that elevated GH levels in patients with liver cirrhosis 
might in part be due to decreased hepatic removal ( Came-
ron et al 1972). In healthy man the liver has been shown 
to be responsible for approximately 50% of the total GH 
clearance (Bratusch-Marrain et al 1979). In this small 
series of patients we were able to confirm the work of 
others (Panerai et al 1977, Zanoboni and Zanoboni-Mucciac-
ca 1977, van Thiel et al 1978) that liver cirrhosis is 
associated with a paradoxical rise in GH levels following 
TRH administration, and furthermore that hepatic removal 
of GH was lower in the cirrhotic group than in the non-
cirrhotic group. Normal metabolic clearance rates have 
been reported in patients with liver cirrhosis ( Owens 
et al 197~, and although the diminished uptake of GH by 
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the liver is probably in part responsible for the raised 
GH levels in cirrhosis, it seems unlikely that impaired 
extraction plays a major role in initiating a paradoxical 
increase. It is more likely that a paradoxical rise of GH 
after stimulation is caused by an abnormal GH secretion. 
Several possible mechanisms come to mind. The first possi-
bility is an impaired feedback mechanism caused by a dimi-
nished somatomedin production in the liver. Elevated GH 
levels together with decreased somatomedin production in 
the liver have been reported by Schimpff et al (1978). 
Although increased somatomedin production took place in 
the kidney, periphe~al vein somatomedin levels were signi-
ficantly lower thanm controls. A negative feedback mecha-
nism by somatomedin is therefore a possibility.A relation 
between increased GH levels andclevated estrogen levels was 
reported (Hernandez et al 1969), however van Thiel et al 
(1978) found a significant increase of GH after TRH in 
cirrhotic patients but not in alcoholic patients without 
cirrhosis, while the estrogen levels in both groups were 
the same. However sex steroid binding protein concentra-
tions were not measured. A third possi~lity is that the 
elevated GH levels in chronic liver disease may be related 
to impaired nutritional status. Basal plasma growth hormo-
ne is elevated in kwashiorkor, which is caused by a lack 
of protein, but not in marasmus. After refeeding GH levels 
return to normal (Raghunamulu and Jaya Rao 1974). In 
chronic liver disease (Wright et al 1968) a direct re-
lationship between low plasma albumin and elevated growth 
hormone has been established. In our small patient group 
no such relation could be found. Both GH and PRL have a 
molecular weight of about 21.5000 and the primary amino 
acid sequence of these two hormones shows many similari-
ties (Niall et al 1973). Despite these resemblances, in 
this group of patients with portal hypertension GH appears 
to be mainly taken up by the liver while PRL is eliminated 
mainly by the kidney (Bauer et al 1980). The mechanisms 
whereby these two polypeptide hormones are removed from 
the circulation by the liver or the kidney remains unclear. 
Specific binding sites for GH have been demonstrated in 
human liver ( Carr and Friesen 1976) but it is not known 
whether these are involved in the clearance of GH. The 
relative specifi~ity of PRL removal by the kidney suggests 
that the process is not solely due to loss via glomerular 
filtration. 
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\0 Table 1: Clinical particulars and laboratory results of the 10 patients undergoing catheterization. 
~ 
cirrhosis noncirrhosis 
patient 1 3 4 5 6 2 7 8 9 10 
pathology alcoholic incomplete macro alcoholic alcoholic steatosis idiopathic hepatic right 'diopathic 
cirrhosis septal nodular cirrhosis cirrhosis hepatis portal schisto- heart portal 
fibrosis cirrhosis hyper- somiasis failure yper-
+ chronic tension ens ion 
a. .... ~.-.uep. 
age (yrs) 44 68 67 46 54 67 64 27 65 67 
sex M M M M M F F M M M 
body weight 67 68 80 67 61 62 104 66 56 85 
(kg) 
wedged H.V.P. 17 19 16 25 12 3 13 1 3 22 
free H.V.P. 
(mmHg) 
bilirubin 80 10 22 100 8 26 11 12 20 10 
(n=12 umol/1) 
normotest 19~ 73% 57% 25% 68% 140% 86% 106% 82% 76% 
albumin g/1 28 46 52.5 29 27.5 32.6 40 52 43 42 
creatinine 108 100 87 64 170 48 72 115 130 99 
(n=60-110 
umol/1) 
basal GH 9.0 0.8 1.6 1.6 6.6 4. 1 1.1 5.2 5.2 3.2 
(ng/ml) 
max GH 23.0 27.7 24.5 2.2 30.7 9.4 4.1 5.3 5.4 6.7 
(after TRH) 
ng/ml 
\!) 
w 
Table II: Mean growth hormone (ng/ml) S.E.M. at 0' and after 400 ug TRH 
0' 10' 
cirrhosis v. per 3.9 ± 1.6 9.6 :!: 3.4 
N = 5 v. hep 3.2:!;1.2 9.2 :!: 3.4 
v. ren 4.1 .± 1.5 9.0 + 3.4 
"10ncirrhosis v. per 3.8:!: 0.8 5.3+1.0 
N = 5 v. hep 3.2 + 0.7 3.9 :!: 0.8 
v. ren 3.0 :!: 0.8 4.2 ± 0.3 
-- --
Statistical significance cirrhosis VP - VH 
VP - VR 
20' 
13.5:!;5.0 
12.5:!: 4.7 
13.2:!: 5.0 
5.1 .± 0.8 
3.7 + 0.8 
4.3:!: 0.7 
p < 0.001 
p < 0.05 
30' 40' 
16.0 :!: 5.6 18.8 ± 4.5 
15.7:!: 5.4 17.3 :!: 4.3 
14.9:!: 4.4 16.6 .± 4.2 
4.0:!: 0.8 4.0:!: 1.0 
3.0 + 0.4 2.9 :!: 0.6 
3.8 ± 0.7 3.7 ± 0.9 
noncirrhosis VP - VH 
VP - VR 
SO' 
19.4 :!: 4.6 
17.6 :!: 4.2 
17.6 .± 4.5 
3.6 + 0.9 
2.7 + 0.6 
3.5 :!: 1.0 
p < 0.001 
p < 0.001 
60' 
15.2 ± 5.3 
15.2 :!: 5.0 
14.8:!: 5.0 
3.3 + 1.0 
2.5 :!: 0.6 
2.8:!: 0.7 
--
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CHAPTER 5 
HYPERPROLACTINEHIA OF PORTAL 
HYPERTENSION IN RATS. 
Hyperprolactinemia of Portal 
Hypertension in Rats 
A. G. C. BAUER. W. J. DE GREEF, F. H. DEJONG, 
J. H. P. WILSON, and S. W. J. LAMBERTS 
Department of Internal Medicine and Department of Endocrinology. Growth and 
Reproduction, Erasmus University. Rotterdam, The Netherlands 
Plasma prolactin levels are often raised in patients 
with liver cirrhosis and portal hypertension. To 
obtain more insight into the underlying mechanisms 
we examined the synthesis and release of prolactin 
in male rats with partially ligated portal veins. 
Portal hypertension led to an increase in pituitary 
prolactin, plasma prolactin, and plasma 17 /3-estra-
diol, and a decrease in hypophyseal stalk dopamine 
levels. Castration decreased plasma prolactin levels 
and prevented the induction of hyperpro!actinemia 
by portal hypertension. Administration of dihydro-
testosterone to castrated animals did not affect pro-
lactin levels in the pituitary gland or in the plasma. 
Plasma tl}'ptophan and tyrosine concentrations did 
not change in portal hypertension. A low protein 
diet caused a decrease in plasma tryptophan and an 
increase in plasma tyrosine levels without affecting 
prolactin levels in either controls or portal hyperten-
sive rats. The hyperprolactinemia of portal hyper-
tension is probably caused by elevated estrogen 
levels which interfere with hypothalamic dopamine 
release. Changes in plasma amino acid levels are of 
little importance in the regulation of prolactin re-
lease in portal hypertensive rats. 
Plasma prolactin (PRL] levels are often elevated in 
patients with cirrhosis of the liver (1-5). Since PRL 
in patients with liver disease is mainly eliminated by 
the kidney (6-8). it is unlikely that the observed 
higher PRL levels are caused by reduced peripheral 
elimination. These patients also have an exaggerated 
response of plasma PRL to thyrotrophin releasing 
hormone (TRH] (2,3,5) and lose the diurnal changes 
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in plasma PRL levels (9,10). Thus elevated PRL 
levels in liver cirrhosis are likely caused by an 
abnormality in the control of PRL release. 
PRL secretion by the anterior pituitary is tonically 
inhibited by the hypothalamus and this inhibition is 
mainly caused by dopamine (11-13). Thus the in-
creased PRL release in liver cirrosis may be caused 
by changes in dopaminergic activity in the central 
nervous system (3). Plasma prolactin levels are much 
higher in cirrhotic patients with hepatic encephalop-
athy than in patients with cirrhosis (14). Several 
authors have suggested that in hepatic encephalop-
athy false neurotransmitters (e.g., octopamine in-
stead of dopamine] might be formed due to a change 
in the ratio of plasma aromatic amino acids to 
branched chain amino acids (15,16). Administration 
of the dopamine agonist bromocriptine has been 
reported to result in improvement of the encepha-
lopathy (16). thus providing evidence in favor of a 
decreased dopaminergic activity of the central ner-
vous system in this type of patient. On the other 
hand estrogen levels are elevated in cirrhosis (17) 
and it is well known that estrogens can stimulate 
PRL release, probably through interference with do-
pamine secretion from the hypothalamus, and 
through a direct effect on the anterior pituitary 
(18-21). 
In the present investigation the possible role of 
changes in dopaminergic control and of increased 
estrogen levels in inducing high levels of PRL were 
studied. In order to eliminate the possible effect of 
liver disease or alcoholism. both factors that may 
lead to elevated prolactin levels, a rat model of portal 
hypertension in which hepatic mass is preserved 
was used (22). Plasma 17{:l-estradiol and hypophyse-
al stalk plasma dopamine concentrations were mea-
sured in these and control animals. Some animals 
were placed on a protein-restricted diet in order to 
change the plasma levels of the amino acid precur-
sors of dopamine and serotinine, whereas otber 
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Table 1. Pituitary PRL Concent Without or After Incuba-
tion with Dopamine in 8 Portal Hypertensive 
and 8 Sham-Operated Rats 
PRL (J.tgirng pituitary) 
Medium 
Pituitary 
gland 
Total 
pituitary 
PRL 
concent 
(J.tg) 
Sham-operated controls 1.82 ± 0.29 1.62 ± 0.30 23.1 ± 1.8 
+ dopamine (500 nm) 0.49 ± 0.10" 2.43 ± 0.45 
Portal hypertension 3.15 ± 0.24" 3.38 ± 0.29" 34.9 ± 3.1" 
+ dopamine (500 nm) 0.36 ± 0.02" 3.38 ± 0.29" 
a p < 0.01 vs. control. 
animals were castrated to cause lower peripheral 
estrogen levels (23). 
Methods 
Male Wistar rats [TNO, Zeist, The Netherlands) 
weighing 202 ± 23 g (mean ± SD) were used. Portal 
hypertension [PH) was induced by partial portal vein 
ligation (21 ); control rats underwent sham operation. 
Spleen weight served as a measure of the success of the 
operation on the portal circulation. Furthermore, portal 
vein pressure measurements were performed via cannula-
tion of the mesenteric vein under ether anesthesia in 5 
sham-operated and 5 portal hypertensive rats. The pres-
sure in the inferior vena cava was taken as a reference. The 
portal vein pressure reported is the difference between 
portal vein pressure and inferior vena cava pressure. 
Experiment 1 
Eight portal hypertensive rats and 8 sham-operated 
rats were studied 3 wk after operation. The rats were killed 
by decapitation, and trunk blood was collected into hepar-
inized tubes for 17{3-estradiol assay. Plasma samples were 
stored at -20"C until assay. The pituitary glands were 
removed, weighed, incubated for 4 h in medium 199 
[Gibco-Biocult, Glascow, Scotland), with or without dopa-
mine, as described previously (12). 
Experiment 2 
Three groups of 8-10 portal lwpertensive rats and 
8-10 sham-operated rats were used. Group 1 rats were fed 
normal chow, group 2 rats, in addition to undergoing 
portal vein ligation or sham-operation, were castrated, and 
group 3 rats were put on a protein-restricted diet (5% 
caseine by weight. Hope Farms, WoerdP-n. ThP- NP-ther-
lands]. Four weeks later all rats were decapitated. Plasma 
was stored at -20'C. The pituitary glands. livers. and 
spleens were removed and weighed. Plasma prolactin 
levels were measured in the pituitary glands. Plasma 
levels of 17 {:l-estradiol. PRL. tyrosine, and tryptophan were 
determined. 
Experiment 3 
Hypophyseal portal blood was sampled in 8 rats 
with portal hypertension and 8 sham-operated umtrol rats 
at a rate of 4-8 J.tllmin for 50 min using the method of 
Porter and Smith (24) with some modifications (11,24) 
while rats were under urethane ( ethylcarbamate, 1.2 g/kg 
body wt) anesthesia. 
Dopamine was measured in the hypophyseal stalk plas-
ma samples. just before cutting the hypophyseal stalk a 
peripheral blood sample was obtained via a cannula in-
serted in the right femoral artery to measure its PRL 
content. 
Experiment 4 
Two groups of 7 castrated portal hypertensive rats 
were established. Group 1 rats were injected subcutane-
ously with 150 f.Lg dihydrotestosterone propionate in oil 
s.c. once daily, while the second group, injected with the 
same amount of oil [0.1 ml) served as controls. 
Assays 
Plasma prolactin levels were measured by a double 
antibody radioimmunoassay using materials and protocols 
supplied by the NIAMDD Rat PRL RP-1. Intraassay varia-
tion in male animals was 4.2% [n = 38, values varying 
between 10 and 30 ng/ml), interassay variation 6.7% (n = 
6). 17{3-Estradiol was measured by radioimmunoassay as 
described previously (23). Dopamine was measured by a 
high performance liquid chromatographic-electrochemical 
method (25) as previously described (26). The intra- and 
interassay variations of these determinations have been 
described in the references cited above (23,26). Tyrosine 
was determined by a fluorometric method (27). Trypto-
phan was measured by a modification of the fluorometric 
method of Denkla and Dewey (28). 
Statistical Analysis 
Results are expressed as mean ± SEM. Statistical 
analysis comprised the nonparametric Wilcoxon test and 
analysis of variance. When significant overall effects were 
obtained with the analysis of variance, comparisons be-
tween groups were made with Duncan·s multiple range 
test. Differences were considered significant when p < 
0.05. 
Results 
Partial ligation of the portal vein resulted in 
significant increases in mean spleen weight (88 ± 
4.5 mg. n = 38) compared with 69.0 ± 3.2 rng in 
controls (n = 38, p < 0.005). In contrast lh·er weights 
remained unchanged (sham 9.68 ± 0.23 g. PI I 9.22 ± 
0.31 g NS). Mean portal pressure (portal vein pres-
sure - inferior vena cava pressure) was 11.9 ± 1.0 
mmHg in the rats with partial ligation of the portal 
vein (n = 5) as opposed to 1.6 ± 0.5 mmHg in the 
control animals (n = 5, p < 0.005). 
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Figure 1. The effect of portal hypertension, castration, and a 5% 
casein diet on pituitary and plasma prolactin. 
Experiment 1 
The results are summarized in Table 1. Total 
pituitary PRL content was increased in the portal 
hypertensive rats. Dopamine inhibited PRL release 
by the pituitary gland in vitro of portal hypertensive 
rats to a similar extent as in control rats. Plasma 17 {3-
estradiol levels were significantly elevated in the 
portal hypertensive rats (17.0::!: 1.6 pg/ml) compared 
with sham-operated controls (11.4 ::!: 1.9 pg/ml) (p < 
0.01). 
Experiment 2 
Total pituitary PRL content and plasma pro-
lactin was significantly higher in portal hypertensive 
than in sham-operated rats (group 1, normal chow) 
(Tables 1 and 2, Figure 1). However. castration 
eliminated the effect of portal hypertension on pitu-
itary PRL content and on plasma PRL levels (group 
2) (Table 2, Figure 1). Castration also lowered plasma 
PRL concentration in control rats (Figure 1). Plasma 
tyrosine and tryptophan levels did not differ be-
tween the portal hypertensive and sham-operated 
rats of groups 1 and 2. Neither portal hypertension 
nor castration affected plasma tyrosine and trypto-
phan levels (Table 2). In the rats on a protein-
deficient diet (group 3) plasma PRL levels and the 
pituitary PRL content were similar to those of group 
1 portal hypertensive and sham-operated controls 
(Table 2, Figure 1); however, plasma tyrosine levels 
were increased and plasma tryptophan h!vels were 
decreased significantly in this group of rats [Table 2). 
No difference in the levels of plasma tyrosine and 
tryptophan existed between portal hypertensive and 
sham-operated rats in group 3 (Table 2). 
Experiment 3 
Hypophyseal stalk plasma dopamine levels 
were significantly lower in the portal hypertensive 
group than in sham-operated controls (3.57 ::!: 0.87 
ng/ml vs. 6.34 ::!: 0.93, p < 0.05). Plasma prolactin 
levels in this group of rats were lower than in 
experiments 1 and 2 while the differences between 
portal hypertensive and sham-operated rats were not 
significant (36.9 ± 11.3 ng/ml vs. 32.3 ::!: 6.7 NS), 
probably due to the urethane anesthesia (29). 
Experiment 4 
Daily substitution with 150 JLg dihydrotestos-
terone (DTHP) in the castrated animals led to a 
significant decrease in pituitary weight compared 
Table 2. The Effect of Portal Hypertension. Castration, and a 5% wt/wt Casein Diet on Body Weight. Pituitary Weight. 
Plasma Tyrosine, and Tryptophan 
Group 1 Group Z 
Mean body w1:ight 
(g =" SlJ) 
Mean pituitar~: Wl!ight 
(mg :o SlJ) 
Mean plasma tryptophan 
(nmoliml :o SE:I.I) 
Mean plasma tyrosirw 
(nmoliml :o SE.\IJ 
Sham 
(n; 9) 
252 = 18 
6.94 = 2.36 
111.8 ± 4.3 
91.2:!: :L4 
Portal 
hypertension 
(n; 9) 
245 = 21 
7.62 ± 0.81 
Sham+ 
castration 
(n; 10) 
234 = 19 
9.84 ± 1.60" 
109.1 "'~.6 110.7 ± 5.6 
I 
90.6 ± 3.4 78.9 "' l.!l 
(J Difft!renct! signific,mt (p · tUl:l) uunpared with group 1 controls. 
PH+ 
castration 
(n; 8) 
240 = 22 
10.05 ± 1.3:!" 
101.7 "' 4.5 
82.1 ± 5.1 
Group 3 
Sham+ 5% 
casein diet 
(n = 10) 
zoo ± 16 
5.11 ::: 0.5801 
PH+ 5% 
Casein diet 
(n = 10) 
180 "' 20 
5.23 :!: 0.67'' 
68.8 "' 4.2" 60.7 = 4.5" 
123.1 "'8.1" 116.5 = 8.3" 
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with controls [DTHP: 6.77 ± 0.34 mg; placebo: 9.01 
± 0.29 mg, p < 0.005), while the pituitary prolactin 
content (DTHP 34.8 ± 2.8 J.Lg; placebo 35.7 ± 2.5 J.Lg) 
was not altered. The plasma PRL levels did not differ 
between both groups. They were, however, higher 
than the groups of castrated rats who were not 
injected. Perhaps as a reaction to the injection stress 
large fluctuations in plasma PRL concentrations 
[DTHP 413.7 ± 136.8 ng/ml; placebo 120.5 ± 47.5 
ng/ml NS) were noted. 
Discussion 
We have shown in the present study that 
portal hypertension without concomitant liver cir-
rhosis induces hyperprolactinemia in rats. This hy-
pcrprolactinemia was associated with increased 
plasma 17 ,/3-estradiollevels and decreased hypophy-
seal stalk plasma dopamine levels. Van Thiel et a!. 
reported that plasma estrone levels are increased in 
rats with portal hypertension (22). The elevated 
estrogen levels found in portal hypertensive males 
arc mainly caused by increased peripheral aromati-
zation of testosterone via androstenedione (30-32) 
and partly by decreased elimination by the liver (33). 
Castration, which causes lower plasma levels of 
estrogens in the male rat (22). led to markedly 
decreased peripheral PRL levels and completely 
blocked the portal hypertension-induced hyperpro-
lactinemia. Supplementation of castrated animals 
with dihydrotcstosterone, a testosterone metabolite 
that cannot be transformed to estrogen in vivo. led to 
a significant decrease of the castration-induced in-
crease in pituitary weight, but did not influence the 
castration-induced fall in pituitary prolactin and 
plasma prolactin levels. This suggests that the effect 
of castration on prolactin levels in the portal hyper-
tensive rat is mediated by changes in estrogen levels 
and is not due to decreased testosterone levels. The 
increase in the pituitary weight of both portal hyper-
tensive and sham-operated castrated rats therefore is 
probably caused by increased gonadotrophin pro-
duction while prolactin production remains low. In 
rats, neurotransmitter levels in the brain arc to a 
large extent dependent on the plasma levels of their 
aromatic amino acid precursors (34,35). This makes 
it possible to influence the concentration of neuro-
transmitters in the brain by diet-induced changes in 
plasma aromatic amino acids. e.g .. tryptophan anc! 
tyrosine levels (36,37). In liver cirrhosis increased 
plasma aromatic amino acids compete with de-
creased branched chain amino acids for carrier 
bound transport through the blood-brain barrier 
(38,39). This leads to increased aromatic amino acid 
levels in the brain. Evidence has been presented that 
excessive levels of the aromatic amino acid and 
dopamine precursor tyrosine in the brain lead to the 
formation of the false neurotransmitter octopamine 
(15,40). 
However in this rat model, portal hypertension 
did not lead to changes in either plasma tryptophan 
or plasma tyrosine, and the false neurotransmitter 
mechanism therefore is unlikely to be responsible 
for the hyperprolactinemia. In vitro experiments, 
furthermore, have shown that octopamine does not 
have an effect on prolactin release by the pituitary 
gland in vitro, nor does it influence the PRL-inhibit-
ing effect of dopamine [S.W.J. Lamberts and R.M. 
MacLeod, unpublished observations). We confirm in 
the present study the observations that severe pro-
tein restriction in rats leads to a fall in plasma 
tryptophan and increase in plasma tyrosine concen-
trations [41,42). This should have caused a decrease 
in central nervous system serotonin [serotonin stim-
ulates PRL secretion) and an increase of the prolactin 
inhibitor dopamine. Plasma and pituitary PRL lev-
els, however, did not change after protein restriction 
and the portal hypertension-induced PRL rise re-
mained intact. 
The present results strongly suggest that the hy-
perprolactinemia induced by portal hypertension 
and the associated fall in hypophyseal stalk dopa-
mine levels are not caused by a change in brain 
neurotransmitter precursor concentrations or forma-
tion of false neurotransmitters but are the result of 
increased plasma estrogen levels. It has been shown 
that estrogens stimulate PRL levels in humans (18). 
Studies in rats indicate that the estrogen-induced 
PRL rise can be blocked by bromocriptine adminis-
tration (19). while incubation of rat anterior pituitary 
cells with 17 ,13-estradiol leads to a reversal of the 
inhibitory effect of dihydroergocornine, a dopamine 
agonist (20). Estrogens also induce a fall in dopa-
mine in hypophyseal stalk plasma (43). An excessive 
rise in PRL after TRH and ether stress in estradiol-
primed rats has been found (21). perhaps as a result 
of the lowered hypothalamic dopamine secretion 
(26,44). These findings suggest that estrogens stimu-
late PRL release. probably through interference with 
the inhibitory effect of dopamine. We have shown 
that prolactin levels in the rat arc elevated in portal 
hypertension without severe liver damage. We con-
clude that this increase is caused by elevated estro-
gen levels through interference with the hypothal-
amic release of dopamine. In this model. changes in 
plasma amino acid levels arc of minor importance in 
PRL regulation. 
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CHAPTER 6. 
HYPERPROLACTINEMIA IN HEPATIC ENCEPHALOPATHY : THE EFFECT 
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CHAIN AMINO ACIDS. 
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ABSTRACT 
Prolactin levels are elevated in patients with liver cir-
rhosis and hepatic encephalopathy. Patients with hepatic 
encephalopathy also have an abnormal plasma amino acid 
ccmposition, with a relative excess of aromatic amino 
acids and a relative decrease in branched chain amino 
acid levels. In order to study the effect of the plasma 
amino acid composition on prolactin release, we measured 
plasma PRL at 0,10,20,30,40,50 and 60 minutes after 400 
ug TRH both after infusion of a conventional amino acid 
mixture and after a branched chain amino acid enriched 
mixture (BCAA) in 5 patients with cirrhosis of the liver 
and hepatic encephalopathy. 
After conventional amino acid infusion, a depressed bran-
ched chain I aromatic amino acid ratio was found in all 
patients, together with an increased PRL response to TRH. 
After the BCAA infusion the branched chain I aromatic ar,,i-
no acid ratio normalized. At the same time the excessive 
PRL response to TRH stimulation was significantly lower in 
all patie::ts. This suggests that the elevated PRL levels 
in hepatic encephalopathy are caused by disturbance of 
hypothalamic neurotransmitter systems, due to altered 
amino acid-neurotransmitter precursor levels. 
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INTRODUCT10N. 
Plasma prolactin (PRL) levels may be elevated in patients 
with cirrhosis of the liver and portal hypertension (1-4). 
Even higher PRL levels have been reported in hepatic ence-
phalopathy (5). In these patients an exaggerated reaction 
to thyrotropin releasing hormone (TRH) stimulation can 
also be found. 
Since PRL elimination in liver cirrhosis i~ not decreased 
(6-8) the elevated PRL levels are probably caused by a 
disturbed PRL secretion. PRL secretion is mainly r2gulated 
by tonic inhibition by hypothalamic factors of which dopa-
min is the most important (9). It is therefore to be ex-
pected that a rise in PRL levels in patients with cirrho-
sis of the liver and hepatic encephalopathy is mediated 
through a loss of the dopaminergic control of prolactin 
secretion. Recently, evidence has been presented that 
hypothalamic dopamine secretion may indeed be abnormal in 
patients with cirrhosis of the liver and hepatic encepha-
lopathy (10,11). 
The hypothesis has been put forward that physiologic neu-
rotransmitter systems in the brain may be disrupted and 
false neurotransmitters may be formed because of a rela-
tive increase of aromatic amino acids in relation to 
branched chain amino acids in the blood (12). This theory 
led to clinical trials with branched chain enriched amino 
acid mixtures (BCAA) , designed to counteract this amino 
acid imbalance in hepatic encephalopathy. Several encoura-
ging results have been reported, although not by all 
groups (13-16). It therefore seemed worthwhile to study 
the effect of such amino acid mixtures on PRL secretion 
in patients with cirrhosis of the liver and mild chronic 
hepatic encephalopathy and to compare the effect with 
those obtained by infusion of ordinary amino acid mixtures. 
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METHODS. 
Five patients (3 men, 2 women) with cirrhosis of the liver 
and mild hepatic encephalopathy were studied. Two of these 
patients had surgical portosystemic shunts months and 
years before the study. Clinical and laboratory particu-
lars are summarised in table I. The diagnosis of liver 
cirrhosis was verified by biopsy in all patients. The 
diagnosis of hepatic encephalopathy was based on the pre-
sence of the following symptoms: disturbed sleep pattern, 
inability to concentrate, slurred speach, flapping tremor, 
an abnormal Reitan trail test (17), and elevated plasma 
amonia levels. All patients were in a stable condition 
without signs of recent gastrointestinal hemorrhage. They 
were maintained on a 40-60 gram protein restricted diet 
and treated with lactulose and neomycine. None of the pa-
tients received drugs known to elevate PRL levels. The 
amino acid mixtures used were a mixture with excess 
branched chain amino acids (amino-steril Hepa 8%R, 
Fresenius, Bad Homburg, West Germany ) (table 2), and a 
mixture with a more conventional amino acid composition 
(Aminess R KabiVitrum, Stockholm, Sweden) (table 2). The 
volume infused was 
the same amount of 
525 ml Aminosteril 
calculated to contain approximately 
nitrogen (1000 ml Aminess R= 6.5 g N; 
R Hepa = 6.7 g N). Both mixtures were 
infused intravenously over a 24 hour period with the aid 
of a peristaltic pump. Patients were randomized to start 
with either of these 2 mixtures and received the alterna-
tive 7 days later. Patients thus served as their own con-
trols. After 24 hours infusion, heparinized, blood samples 
were taken at 0,10,20,30,40,50 and 60 minutes after the 
R intravenous injection of 400 ug TRH ( Relefact ) , cen-
trifuged and stored at -20°C until assay. Normal values 
for basal PRL and maximal PRL after TRH were obtained 
from 14 healthy volunteers (7 males, 7 females). The amino 
acid composition of the blood was determined in plasma 
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samples taken immediately prior to the TRH injection after 
the BCAA-enriched amino acid infusion and after the con-
ventional amino acid infusion. From these findings, a 
branched chain amino acid ratio (BCAA/AAA) was calculated 
according to the equation: 
valine + leucine + isoleucine 
( 12). 
tyrosine + phenylalanine 
Normal values for the BCAA/AAA ratio for healthy adults 
were derived from Soeters (15). 
ASSAYS. 
PRL levels were measured in duplicate immunoassay (normal 
values, up to 12 ng/ml in males and up to 15 ng/ml in 
females) . The intraassay varia tion of determination was 
4.5% (50 duplicates; 2-50 ng/ml), and the interassay 
variation was 3.8% (mean 14 ng/ml, n = 12). 
Plasma amino acid levels were determined with the aid of 
a Technicon TSMI amino acid analyser. 
STATISTICAL ANALYSIS. 
The difference between TRH stimulated PRL levels after 
BCAA-enriched amino acids infusions and conventional amino 
acid infusions was assessed by Student-s paired t test in 
each individual and in the patient group as a whole. 
The differences between basal PRL levels in normal con-
trols, and in patients after BCAA-enriched amino acid in-
fusion and after conventional amino acid infusions were 
assessed with the non parametric Mann-Whitney test. Diffe-
rences betweenAPRL were assessed similarly in these three 
groups. The differences in amino acid composition of the 
blood after conventional amino acid infusion and after 
BCAA-enriched amino acid infusion were assessed by Student-s 
paired t test for each individual amino acid. The differen-
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ce between the BCP~ to AAA ratio after both amino acid 
infusions were also assessed by Student-s paired t test. 
RESULTS. 
The results are summarized in fig. 1 and table 3 and 4. 
Basal PRL levels were not elevated in these patients in 
comparison with normal controls and did not differ signi-
ficantly between BCAA-enriched amino a·cid and conventio-
nal amino acid periods. After TRE 1 PRL levels were signi-
ficantly higher following the conventional amino acid 
mixture compared to normal controls ( p( 0 105) whereas 
in the BCAA-enriched treatment period this difference dis-
appeared. The difference in PRL levels after TRE between 
the conventional amino acid and BCAA enriched treatment 
periods were significant in all five patients (p( 0.001 
in 2 pts. 1 p < 0. 0 0 5 in 2 pts. 1 p ( 0. 0 5 in 1 pt. ) and in 
the group as a whole ( p ( (:. 0 01) • .P"fter conventional amino 
acid infusion the plasma a~ino acid pattern showed a rela-
tive excess of P~ and a relative decrease of BCAA in all 
patients (table 4). The BCAA/AAA ratio was depressed in 
all patients (15). After BCAA enriched infusion the ~J" 
levels decreased (phenylalanine p( 0.02 1 tyrosine 
P( 0.05). The BC.I'-.1'_ levels increaseC:. in 4 out of the 5 
patients (valine p( 0.05 1 leucine n.s. 1 isoleucine n.s.), 
while the BCAA/AAA ratio rose in all patients and norma-
lized in 4/5 of the patients ( P< 0.05). 
DISCUSSION. 
PRL levels are often elevated in cirrhosis of the liver 
and may be even higher in hepatic encephalopathy (1-5) In 
our small group of patients basal PRL levels were not 
elevated. However after TRB stimulation following infusion 
of a conventional amino acid mixture, PRL levels rose 
significantly higher than in normal controls, PRL 
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release is regulated by inhibitory and releasing hypotha-
lamic factors in which the inhibiting effect of dopamine 
is the most important (9). To explain the excessive rise 
of PRL levels after TRH stimulation in hepatic encephalo-
pathy it is therefore attractive to postulate a disturban-
ce of th~ dopaminergic neurotransmitter system. Indirect 
evidence has been presented that hypothalami~ dopamine 
release may indeed be disturbed in cirrhosis of the liver 
with hepatic encephalopathy (10,11,17). In hepatic ence-
phalopathy changes in amino acid balance are thought to 
lead to changes in central neurotransmitter systems. This 
theory is based on evidence that in hepatic encephalopa-
thy AAA (tryptophan, phenylalanine and tyrosine) are in-
creased in relation to the BCAA (valine, leucine and iso-
leucine)) (12,14,19). Since these amino acids all compete 
for the same carrier through the blood-brain barrier (20) 
this will result in an excess of aromatic amino acid 
neurotransmitter precursors in the brain. Because tyrosine 
is the precursor for catecholamines (21) and tryptophan 
the pre8ursor for serotonin (22) these changes should 
substantially influence neurotransmitter levels. It has 
been suggested that the production rate of dopamine in the 
brain is limited, and that excess tyrosine will be conver-
ted to the false neurotransmitter octopamine, instead of 
dopamine (10,11). On the other hand elevated levels of 5-
hydroxy indole acids in the cerebra spinal fluid in cirr-
hosis indicate an increased production and turnover of 
serotonin (23,24). A relationship has been established in 
cirrhosis of the liver between free plasma tryptophan le-
vels and PRL levels (2). PRL release can be stimulated by 
intravenous administration of L-tryptophan (25) and 5-
hydroxy tryptophan (26,27). It is therefore likely that 
both decreased dopamine levels and/or increased serotonin 
levels play a role in the hyperprolactinemia of liver 
cirrhosis, especially in hepatic encephalopathy. In favour 
of this amino acid/neurotransmitter hypothesis is the 
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reported improvement in the level of consciousness of 
encephalopathic patients following administration of 
bromocriptine, a dopamine agonist (28) and BCAA-enriched 
amino acid mixtures (13,14,15). 
In our study the plasma BCAA/AAA ratio was indeed found 
to be severely depressed after infusion of a conventional 
amino acid mixture, while infusion of a BCAA enriched ami-
no acid mixture led to an improvement of .the plasma amino 
acid pattern and an increase of the BCAA/AAA ratio. At 
the same time the PRL response to TRH stimulation was nor-
malized or substantially lowered in all patients. We thus 
present indirect evidence that the elevated PRL levels 
found in patients with cirrhosis of the liver and hepatic 
encephalopathy are caused by a disturbance of hypothalamic 
dopamine and possibly also serotonin release, which is 
probably caused by a change in the amino acid-neurotrans-
mitter precursor levels in the brain. Since octopamine 
does not have an effect on PRL release in vitro and also 
does not influence the PRL inhibiting effect of dopamine 
in vitro ( S.W.J.Lamberts and R.M.MacLeod, unpublished 
observations), it seems less likely that the disturbance 
of prolactin secretion is caused by the formation of false 
neurotransmitters per se. It is however possible,that 
the abnormal amino acid levels are not the only factor 
contributing to the hyperprolactinemia of cirrhosis;since 
we have found in a study of portal hypertensive rats that 
the increased estrogen levels associated with portal hy-
pertension lead to elevated PRL levels ttrcunh decreased 
hypothalamic dopamine release (29)yit seems likely that 
increased estrogen levels also play a role in the increa-
sed PRL levels in cirrhosis of the liver. 
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Table I. Clinical and laboratory particulars of 5 patien~with 
cirrhosis of the liver and mild chronic encephalopathy. 
patient 1 2 3 4 5 
age 75 33 53 51 53 
sex F F M M M 
diagnosis cryptogenic alcoholic alcoholic alcoholic chronic 
micronod. micronod. micronod. micronod. hepati-
cirrhosis cirrhosis cirrhosis cirrhosis tis w:i!h 
I c~rrho-
SlS 
~:--flapplng 
remor - - + + + 
sleep dis- + + + + + 
turbancies 
~orget-full-
ess/concen- + + + + + 
ration dis. 
slurred 
speech - - + - + 
Reitan trail 
test 1 min. + + + + + 
?arices - + + + + 
portocaval 
+ - - + -
shunt 
albumin (g/1) 32 41 30 36 42 
!bilirubin 
umol/1, 19 23 26 85 41 
N 12 
arterial 
ammonia 84 52 60 66 120 
umol/1 
n=l0-30 
SGOT (IE) 49 33 44 42 34 
n= 15-25 
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Table 2. Amino acid composition of AminessR and 
R Aminosteril Hepa 8% . 
Conventional amino acid 
mixture 
(AminessR) 
L-histidine 4.12 g 
L-isoleucine 5.25 g 
L-leucine 8.25 g 
L-lysine 6.0 g 
L-methionine 8.25 g 
L-phenylalanine 8.25 g 
L-threonine 3.75 g 
L-tryptophan l. 88 g 
L-valine 6.0 g 
acetic acid 0.3 g 
volume 1000 ml 
Total N content 6.5 g/1 
BCAA enriched amino acid 
mixture 
(Aminosteril Hepa 8%R) 
L-histidine 2.80 
L-isoleucine 10.40 
L-leucine 13.09 
L-lysine 6.88 
L-methionine l. 10 
L-phenylalanine 0.88 
L-threonine 4.40 
L-tryptophan 0.70 
L-valine 10.08 
L-arginine 10.72 
L-cysteine hydro- 0.75 
chloride 
L-glycine 5.82 
L-alanine 4.64 
L-proline 5.73 
L-serine 2.24 
Acetic acid 7.25 
volume 1000 
Total N content 12.9 
g 
g 
g 
g 
g 
g 
g 
g 
g 
g 
g 
g 
g 
g 
g 
g 
ml 
g/1. 
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0 0' 10' 
Plasma prolactin (ug/1) 
patient 1. conventional 116.9 
BCAA enrichedl13.7 
2. conventional 7.9 
BCAA enriched! 8.0 
3. conventional 110.4 
BCAA enrichedl11.8 
4. conven tiona! 6.0 
BCAA enriched! 3.7 
5. conventional 4.8 
BCAA enriched! 1.8 
68.5 
46.6 
25.6 
19.4 
75.6 
70.4 
166.4 
48.6 
38.0 
23.0 
Basal PRL (mean+ S.D.) 
mean + S.D. 
I - --
controls 
conventional 19.2 ~ 4.8]-
BCAA enriched 7.8 + 5.0 
males (n=7) 
females (n=7) 
4.6 
7. 1 } 
20' 
74.8 
55.5 
29.3 
24.5 
93.0 
85.3 
210.8 
58.6 
n.s. 
50.9 
27.0 
30' 
82.5 
38.0 
26.4 
21.6 
77.9 
75.2 
289.2 
64.2 
57.6 
28.2 
/:;,. PRL 
40' 
63.7 
41.9 
25.3 
20.7 
77.0 
59.0 
204.3 
48.6 
58.5 
23.0 
50' 
63.3 
32.2 
26.6 
20.9 
46.8 
44.5 
188.8 
44.9 
51.8 
18.3 
p <. 0.05 
,..f110.5 ~ 102.8] 
ll. 51.5 + 25.4 
n.s. [
43.6 + 
'- -
22.9 + 
20.7 
17.6 
60' 
56. 1 
32.2 
20.2 
12.8 
60.5 
39.1 
217.3 
41.5 
39.6 
19.6 
Table 3. PRL levels at 0,10,20,30,40,50 and 60 minutes after 400 ug TRH i.v., following 24 hour 
infusion of BCAA enriched and conventional amino acid mixtures in 5 patients with liver 
cirrhosis and hepatic encephalopathy. 
p < 0.005 
p < 0.001 
p < 0.05 
p <. 0.001 
p < 0.005 
p <. 0.001 
BCAA AAA 
I I --------------, 
I -------
methionine .I valine leucine isoleucine phenylalanine tyrosine BCAA/AAA ratio 
onven- BCAAen- conven- BCAAen- ·~onven- BCAAen- conven- BCAAen- conven- BCAAen- conven- BCAAen- conven- BCJIAenil 
ional riched tional riched tional riched tional riched tional riched tional riched tional riched 
pt 1 0.27 0.45 0.13 0.30 0.07 0.18 0.26 0.09 0.09 0.08 1. 34 5.47 0.28 0.05 
2 0.32 0.45 0. 19 0.23 0.14 0. 17 0.32 O.OB 0.13 0.09 1. 44 5.00 1.03 0.03 
3 0.16 0.39 O.OB 0.21 0.05 0.12 0.13 0.05 0,06 0.05 1. 52 7.20 0.29 o.oo 
4 0.23 0.27 0.10 0. 14 0.04 0.07 0.14 0.07 0.21 0.13 1.05 2.40 0.40 0.00 
5 0.30 0.27 0.20 0. 13 0. 13 0.06 0.34 0.12 0.21 0.17 1. 14 1. 58 0.62 0.07 
mean 
0.26+ 0.14+ 0.09+ 0.12+ 0.24+ 0.08+ 0.14+ 0.10+ 1.29+ 4.33+ 0.52+ 0.03+ ± S.D. 0.37+ 0.20+ 0.06 0.09 0.05 0.0 0.05 0.05 o.'io 0.02 0.07 0.05 0.19 2.30 0.31 0.03 
p <0.05 n.s. n.s. p < 0. 02 p <. 0. 05 p < 0. 05 p < 0.02 
threonine serine glycine alanine glutamine proline 
pt 1 0.37 0.30 0. 15 0.21 0.21 0.38 0.41 0.50 0.45 0.17 0.25 0,53 
2 0.35 0.28 0.11 0. 19 0.20 0.34 0.41 0.37 0 0.15 0. 19 0.32 
3 0.18 0.25 0.13 0.22 0.20 0.34 0.40 0.41 0.25 0.38 
4 0.28 0.23 0.23 0.24 0.22 0.28 0.33 0.36 0.21 1. 45 ' 0.28 0.52 
5 0.31 0.24 0. 14 0.18 0.21 0.25 0.32 0.51 0.38 0.73 0.23 0.41 
I 
mean 0.30+ 0.26+ 0.15+ 0.21+ 0.21+ 0.32+ 0.37+ 0.43+ 0.26+ 0.55+ 0.24+ o. 43+ 
± S.D. 0.07 o.li o .lis o.li o.o'i o.lis 0.04 0.07 o.2o 0.56 0.04 o.'io 
n.s. p < 0.01 p < 0. 02 n.s. 
----
Table 4. Plasma amino acids(urnol/ml) in 5 patients with liver cirrhosis and hepatic encephalopathy 
after 24 hr infusion of BCAA-enriched and conventional amino acid mixtures. 
Figure l. Plasma prolactin levels following TRH stimula-
tion, after infusion of a conventional mixture of amino 
acids (Aminess) or a branched chain amino acid enriched 
mixture (Aminosteril). 
11 2 
PRL 
(ng/ml) 
110 
90 
70 
50 
30 
10 
0 
I 
I 
I 
mean± SEM 
(n = 5) 
r___-L---l ____ ~ 
/ -----6._ T 
1 ---o 
10 
__..._Ami ness 
-c- Aminosteri I 
20 30 40 50 60 minutes 
References. 
1. Van Thiel DH, Gavaler DS, Lester R, Loriaux DC, Braun-
stein GD. (1975) 
Plasma estrone, prolactin, neurophysin and sex-steroid 
binding globulin in chronic alcoholic man. 
Metabolism 24: 1015. 
2. Panerai AE, Salerna F, Hannischi M, Cocchi D, Muller 
EE, a_977 .) 
Growth hormone and prolactin responses to thyrotropin 
releasing hormone in patients with severe liver dis-
ease. 
J.Clin. Endocrinol. Metab. 45 134. 
3. Wernze HF, Schmitz F,( 1977.) 
Plasma prolactin and prolactin release in liver cirr-
hosis. 
Acta Hepato-gastroenterol 24 : 97. 
4. ~1organ MY, Jacobovits AW, Gore MBL, Wills MR, Sherlock 
s, (1.97 8 .) 
Serum prolactin in liver disease and its relationship 
to gynecomastia. 
Gut 19 : 170. 
5. Hacclain CJ, Kromhout JP, Van Thiel D,( 1979.) 
Serum prolactin concentration in portal systemic en-
cephalopathy. 
Gastroenterology 76 1292. 
6. Bratusch-Marrain P, Bjorkman 0, Waldhalisl W, Wahren J, 
(1979 .) 
Hepatic disposal of endogenous growth hormone and 
prolactin in man. 
Eur.J.Clin.Invest. 9 : 257. 
7. Bauer AGC, Wilson JI!P, Lamberts SWJ ,( 1980 .) 
The kidney is the main site of prolactin elimination 
in patients with liver disease. 
J.Clin.Endocrinol.Metab. 51 : 70. 
113 
8. Cowden EA, Ratcliffe WA, Ratcliffe JG, Dobbie JW, 
Kennedy AC, (19 7 8 .) 
Hyperprolactinemia in renal disease. 
Clin. Endocrinol 9 : 241. 
9. MacLeod RM, (1976~ 
Regulation of prolactin secretion. 
In: Martini L, Ganong WF (eds) 
Frontiers in neur<)endocrinology, Raven Press, New York, 
vol 4 p 169. 
10. Fischer JE, Baldessarini RJ,(1971~ 
False neurotransmitters and hepatic failure. 
Lancet ?. : 75. 
11. Mangr .. ani KK, Lunzer MR, Billing BH, Sherlock s,-(1975~ 
Urinary and serum octopamine in patients with portal 
systemic encephalopathy. 
Lancet 2 : 943. 
12. Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, 
Soeters PB, (1976 l 
The effect of normalisation of plasma amino acids on 
hepatic encephalopathy in man. 
Surgery 80 : 77. 
13. Fiene R, HolmE, Dietl H, Mezitis N, Schuler A,(1977) 
Parenterale Ernahrung mit Aminosauren bei Leber In-
suffizienz. 
Verh. Dtsch, Ges.Inn.Med. 83: 533. 
14. Fischer JE, Yoshimura JE, Aguirre A, James JH, Cummings 
MG, Abel RM, Deindoerfer F,(1974) 
Plasma amino acids in patients with hepatic encephalo-
pathy ; effects of amino acid infusions. 
Am.J.Surg. 127 : 40. 
15. Soeters PB,(1979~ 
Hepatic encephalopathy; a new perspective for therapy. 
MD Thesis, Maastricht, The Netherlands. 
16. Michel H, Pomier-Layrargues G, Duhamel 0, Lacombe B, 
Guilleret G, Bellet H,(1980.) 
Intravenous infusion of ordinary and modified amino 
11 4 
acid solutions in the management of hepatic encephalo-
pathy (controlled study, 30 patients). 
Gastroenterology 79 : 1038. 
17. Conn H0,(1977.) 
Trailmaking and number-connection tests in the assess-
ment of mental state in portal systemic encephalopathy. 
Am.J.Dig.Dis. 22 : 541. 
18. Dodsworth JM, James JH, Cummings MG, Fischer JE,(1974l 
Depletion of brain norepinephrine in acute hepatic coma. 
Surgery 75 811. 
19. Daniel PM, Love ER, Moorehouse SR, Ratt OE,(1975l 
Amino acids, insulin and hepatic coma. 
Lancet 2 :179. 
20. Partridge WM,(1977l. 
Kinetics of competitive inhibition of neutral amino-
acid transport across the blood-brain barrier. 
J.Neurochem. 28 : 103. 
21. Wurtman RJ, Larin F, Mortafapour S, Fernstrom JD ,(1974) 
Brain catechol synthesis : control by brain tyrosine 
concentration. 
Science 185 : 183. 
22. Fernstrom JD, Faller DV, Shabske Lowits H,(1975l. 
Acute reduction of brain serotonin and 5HIAA following 
food consumption : correlation with the ratio of 
serum trytophan to the sum of competing neutral amino 
acids. 
J.Neural. Transm. 36 : 113. 
23. Knell AJ, Davidson AR, Williams R, Kantamanei BD, 
Curzon G,(1974.) 
Dopamine and serotonin metabolism in hepatic encepha-
lopathy. 
Br. Med. J. 1 : 54 9 
24. Lal S, Young SA, Sourkes TL,(1975l 
5-Hydroxytryptamine and hepatic coma. 
Lancet 2 : 979. 
1 1 5 
25. Macindoe JH, Turkington RW,( 1973.) 
Stimulation of human prolactin secretion by intrave-
nous infusion of 1-tryptophan. 
J.Clin.Invest. 52 : 1972. 
26. Kato Y, Nahai Y, Imura H, Chihara K, Ohgo S,( 1974.l 
Effect of 5 hydroxytryptophan (5-HTP) on plasma pro-
lactin levels in man. 
J.Clin.Endocrinol.Metab. 38 : 695. 
27. Lancranjan I, Wirz-Justice A, Puhringer W, del Pozo E, 
( 1977.) Effect of 5-hydroxytryptophan infusion on growth 
hormone and prolactin secretion in man. 
J.ClinJndocrinol.Metab. 45 : 588. 
28. Morgan MY, Jacobovits AW, James IM, Sherlock S,( 19801 
Succesful use of bromocriptine in the treatment of a 
patient with chronic porta-systemic encephalopathy. 
Gastroenterology 78 : 663. 
29. Bauer AGC, de Groot WJ, de Jong FH, Wilson JHP, 
Lamberts SWJ,(1982l 
Hyperprolactinemia of portal hypertension in rats. 
Gastroenterology 82 : 179. 
CHAPTER 7 
THE EFFECT OF TAMOXIFEN ON PROLACTIN SECRETION IN CIRRHOSIS 
OF THE LIVER. 
A.G.C.Bauer, J.H.P.Wilson, S.1'if.J.Larnberts, 
Department of Internal Medicine; ERASMUS University, 
Rotterdam, The Netherlands. 
Submitted for publication 
in Gastroenterology. 
1 17 
SUHHARY. 
In order to study the relationship between plasma prolac-
tinlevels and the gynecomastia of liver cirrhosis, 7 male 
patients with cirrhosis of the liver with ( 4 patients ) or 
without ( 3 patients) gynecomastia were studied before and 
after treatment with the anti estrogen, tamoxifen. Treat-
ment with tamoxifen led to a significantly lower PRL res-
ponse to TRH stimulation in all patients with gynecomastia 
but inwne of the patients without gynecomastia (p 0.01) 
irrespective of wether the original response to TRH sti-
mulation was normal or exaggerated. Furthermore in 3 pa-
tients with gynecomastia the breasts became softer and less 
painful. This suggests that the absolute plasma PRL levels 
do not determine the role of PRL in the pathogenesis of 
gynecomastia in liver cirrhosis, but rather its relation 
to other factors, such as an increased estrogen/testoste-
rone ratio. 
INTRODUCTION. 
The most striking hormonal syndrome associated with 
cirrhosis of the liver is the feminization process which 
occurs in up to 40-50% of male patients (1,2). Ttis syn-
drome is characterized by a feminine distribution of hair, 
palmar erythema, the formation of spider naevi, disturbed 
gonadal function, impotence and infertility. In 25-50% 
of patients gynecomastia develops (1-3). The pathogenesis 
of these changes is not fully understood, although a dis-
turbed estrogen/testosterone ratio has been implicated (4). 
On the other hand prolactin levels are often elevated in 
patients with cirrhosis of the liver (3,5,6}, especially 
after TRH stimulation (6,7). Since prolactin plays a phy-
siological role in both breast formation, lactation and 
normal gonadal function, it seems reasonable to expect a 
role for prolactin in the pathogenesis of gynecomastia. 
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Eowever not all patients with cirrhosis of the liver have 
elevated prolactin levels, nor do all patients with hyper-
prolactine~ia develop gynecomastia (3). It seems likely 
therefore that if hyperprolactiner:lia is indeed implicated 
in the pathogenesis of gynecocastia in liver cirrhosis it 
will be in co6peration with other factors, such as a dis-
turbed estrogen I testosterone balance. It is not yet ful-
ly understood why prolactin levels are elevated in 
cirrhosis of the liver, although a disturbance of secre-
tion is more likely than a disturbed elimination (9). We 
recently provided evidence (8) that in rats with portal 
hypertension elevated estrogen levels cause elevated pro-
lactin levels through interference with hypothalamic 
dopamine release. Since elevated estrogen levels therefore 
seem to play a pivotal role both in stimulatinq prolactin 
release in portal hypertension and in the feminization 
process itself, we decided to study the release of prolac-
tin before and after treatment with the anti estrogen 
tamoxifen in patients with cirrhosis of the liver with 
and without synecomastia. 
1·1ETHODS. 
Seven men with chronic alcoholic liver cirrhosis (labora-
tory and clinical particulars table I) were studied 
(age 41-73 ) . All had stopped alcohol consumption at 
least half a year previously and nor-.c showed evidence of 
hepatic encephalopathy. The diagnosis of cirrhosis vlas 
confirmed by biopsy in all patients. Although all patients 
showed testicular atrophy, palmar erythema and varying 
degrees of spider naevi formation, four of the patients 
had gynecomastia while three did not. None of the patients 
used drugs known to elevate prolactin levels or to cause 
gynecomastia. 
Heparinized blood samples were taken at 0,10,20,30,40,50 
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and 60 minutes after 400 ug TRH (Relefact, Hoechst) i.v. 
both before and after treatment with tamoxifen (Nolvadex 
I.C.I.) 10 mg. twice daily during 1 week. 
ASSAY. 
Duplicate PRL levels were measured by radioimmunoassay 
(normal values, up to 12 ug/ml in males. The intra assay 
variation of determinations was 4.5%; (50 duplicates, 
2-50 ug/ml, and the inter assay variation was 3.8% (mean 
14 ug/ml; u = 12). 
STATISTICAL ANALYSIS. 
The difference between TRH stimulated PRL levels before 
and after treatment with tamoxifen was assessed by student-s 
paired t-test. The difference in prolactin release after 
treatment with tamoxifen in the group of patients with 
gynecomastia and the group without gynecomastia was asses-
sed by Fisher-s exact propability test. 
NORMAL VALUES. 
Normal values for PRL were obtained from 7 healthy men: 
Normal basal plasma PRL values were less 12 ug/ml (mean 
4.6 ug/ml) and maximal values after TRH stimulation between 
8.6 and 57.6 ug/ml ( mean+ S.D. 22.9 + 17.6 ug/ml ) . 
RESULTS (table 2) 
Basal PRL levels were normal in all patients studied. Af-
ter TRH stimulation an exaggerated PRL reponse was found 
in 3 patients ( 2 with gynecomastia, 1 without gynecomas-
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tia). Following treatment with tarnoxifen the PRL response 
to TRH stimulation was significantly lowered in 4 out of 
4 patients with gynecomastia ( p<0.01 in 1 pt, p<: 0.001 
in 2 pts, P< 0.05 in 1 pt.) but inrPne of the 3 patients 
without gynecomastia ( p < 0.01 2 tailed Fisher exact test) 
irrespective of the original normal or exaggerated PRL 
response to TRH before treatment with tarnoxifen. In 3 
patients with gynecomastia (pt 1,2 and 4) the breasts be-
carne softer and smaller and painfulness disappeared after 
one week of treatment with tarnoxifen ( 20 rngjday). 
DISCUSSION. 
Estrogens stimulate PRL secretion in male and female agona-
dal subjects ( 9,10) and elevate basal prolactin levels in 
normal menstruating women (11). In vitro studies show that 
estrcgens enhance the stimulating effect of TRH on PRL 
stimulation (12,13,14). Estradiol 17B has a direct effect 
on PRL secretion in rat pituitary cell cultures (15,16). 
Apart from this direct effect of estrogens on the pitui-
tary, there is also evidence indicating an effect on pro-
lactin release at a higher hypothalamic level (17,18) pro-
bably through interference with hypothalamic dopamine 
secretion (19). 
In cirrhosis of the liver, estrogen levels are often ele-
vated, mainly through increased peripheral arornatization 
of testosterone via androstenedione (20,21). Recently we 
found in rats that elevated estrogen levels induced by 
portal hypertension lead to increased PRL secretion 
through interference with hypothalamic dopamine release 
(22). It seems therefore reasonable to expect a role for 
estrogens in the elevated PRL levels sometimes found in 
cirrhosis of the liver, especially as estrogen levels are 
elevated in + 60 % of patients with cirrhosis of the 
liver (2). 
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In this study we report the effect of the antiestrogen 
tamoxifen on prolactin release in 7 patients with cirrho-
sis of the liver, divided in a group of 4 patients with 
gynecomastia and 3 patients without gynecomastia. The non-
steroidal anti-estrogen tamoxifen lowers basal but espe-
cially TRH stimulated PRL levels in both animals (23,24), 
and man (25,26,27). 
The anti-estrogenic effect is exerted by competition at 
the estrogen receptor (28) and estrogen levels may even 
rise during administration (25). It has been shown in 
vitro that tamoxifen does not influence prolactin secre-
tion by rat pituitary tumor cells directly but that it 
enhances the sensitivity of these cells to dopamine and 
bromocriptine (29). This enhancing effect can be preven-
ted by coincubation with estradiol 17-B. In addition 
tamoxifen prevents the stimulatory effect of TRH on pro-
lactin secretion (29). We found that tamoxifen signifi-
cantly reduced the prolactin surge after TRH stimulation 
in all patients with gynecomastia but in none of the pa-
tients without gynecomastia, irrespective of whether the 
original PRL response to TRH before treatment was normal 
or exaggerated. In the responder ( gynecomastia ) group 
2 patients had an exaggerated PRL surge, whereas in the 
non-responder ( no gynecomastia ) 1 patient showed an 
excessive rise after TRH. Furthermore in 3 patients with 
gynecomastia the breasts became softer and less painful. 
From these findings it appears that prolactin indeed 
plays a role in the pathogenesis of gynecomastia but that 
not the absolute PRL levels determine its effect but rather 
the relation to other factors. 
It is interesting in this respect that a disturbed 
estrogen I testosterone balance with increased estrogen 
levels and decreased testosterone levels has been found 
to increase prolactin receptor activity (30,31). It seems 
worthwhile on these theoretical grounds, the observations 
made in some patients and the fact that no significant 
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side effec$have been described, to conduct a trial of 
tamoxifen in gynecomastia ( and impotence ? 
with cirrhosis of the liver. 
associated 
Table I. 
PATIENT 2 3 4 5 6 7 
AGE 50 44 73 54 41 62 45 
P.A. Alcoholic Ale. Ale. Ale. Ale. Ale. Ale. 
DIAGNOSIS cirrhosis cirrh. cirrh. cirrh. cirrh. cirrh. cirrh. 
GYNECO- + + + + 
MASTIA 
ERYTHEMA + + + + + + + 
PALMARE 
SPIDER ++ + ++ + ++ ++ + 
NAEVI 
ATROFIA + + + + + + + 
TESTIS 
SGOT u:l 40 25 33 48 45 48 98 
(N5-30) 
BILIR 24 16 13 11 34 13 50 
(umol/1) 
N 2-12 
ALB g/1 35 37 42.2 45 43 37.7 38.2 
table I. clinical and laboratory particulars of 7 male patients with 
liver cirrhosis with (pt 1-4) and without (5-7) gynecomastia. 
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PROLACTINE ug/L 0' 10' 20' 30' 40' 5(!)' 60' 
-,- I B 5.9 21.8 22.5 18. 1 14.6 15.5 14.2 
Patient 1 p < 0.01 
A 3.8 17.6 15.3 15.6 13.6 12.5 10.6 
B 8.5 48.3 54,0 52.2 60.0 51.2 53.5 
Patient 2 p < 0.001 
~ A 4.5 19.0 33.9 30. 1 29.7 25.1 30.8 
H 
E-o 30.6 27.9 26.1 20.6 ~ I Patient 3 B 6.8 24.3 28.9 p < o. 001 
A 6. 1 19.2 21.1 21.0 18.9 16.4 14.6 ~I B 4.2 43.8 50.2 48. 1 40.0 38.3 33. 1 
Patient 4 p < 0.05 
A 4.6 44.4 42.6 42.6 39.0 32.4 30,3 
B 0.1 19.8 28.7 27.4 21.4 17.4 14.8 
Patient 5 
A 1.7 26.1 31.2 30.3 26.6 23.5 21.0 
~ B 3, 1 3.6 7.2 6.7 5.6 5.6 4.1 H 
E-o Patient 6 Ul 
~ A 10.0 10.6 11.0 11.9 7.4 5.5 5,8 
0 
u 
21.7 ~ I Patient 7 B 5.0 37.2 44.7 45.0 40,9 29.1 
A 1.7 38.6 44.3 42.7 40.3 32.8 30.5 @ 
'--
TABLE 2. Prolactin levels (ug/1) at 0,10,20,30,40,50 and 60 minutes after 400 ug TRH iv 
before (b) and after (a) Tamoxifen twice daily during 1 week. 
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CHAPTER 8 
GENERAL DISCUSSION AND CONCLUSIONS. 
The review of literature has shown that basal prolactin 
levels in ci·rrhosis of the liver may be normal or millly 
elevated, while prolactin levels may be excessively raised 
after TRH stimulation (1,2,3). In the present study we 
confirmed these findings. Basal prolactin levels were not 
significantly raised in cirrhotic patients compared to 
normal controls (table I). However after TRH maximal pro-
lactin levels were significantly higher in the cirrhotic 
patients (table I). Furthermore prolactin levels were 
much higher in patients with cirrhosis with hepatic ence-
phalopathy compared to cirrhosis without encephalopathy 
(table I). These findings by themselves already suggested 
a disturbance of prolactin secretion and synthesis in 
cirrhosis of the liver. Nevertheless a decrease of pro-
lactin elimination by the diseased liver had to be exclu-
ded. In chapter 3 we described a study of catheterizations 
in patients with cirrhosis of the liver and portal hyper-
tension, in whom arterio-venous differences across the 
liver and the kidney were studied. As both these organs 
show substantial uptake of radio-iodinated prolactin in 
rodents (4), it was expected that both organs are impor-
tant in prolactin elimination. In cirrhotic patients a 
significantly larger arterio-venous prolactin deficit 
was found across the kidney, than across the liver, while 
these findings were not influenced by the degree of liver 
failure. In two patients without severe liver failure the-
se catheterization studies were combined with hepatic and 
renal plasma flow studies. In this way a renal extraction 
of prolactin of 186 ug/60 min. and 94 ug/ 60 min., and a 
hepatic extraction of 16.4 ug/60 min, and 11.4 ug/60 min. 
respectively was found while liver and kidney perfusion 
were within the normal range. These findings correspond 
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Figure 1. Basal and maximal prolactin levels after TRH, in 
cirrhotic males with and without hepatic encephalopathy, 
and in healthy controls. 
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well with the prolactin production rates found in normal 
2 
man by Cooper et al (males 187 + 44 ug/d/m , females 211 
+ 74 ug/d/m2 ) and suggest that most circulating prolactin 
is eliminated by the kidney, both in cirrhotic and normal 
subjects. This is further substantiated by the fact that 
prolactin levels in kidney disease are inversily related 
to the creatinine clearance and normalise aft~kidney 
transplantation (6,7). In contrast no significant arterio-
venous transhepatic prolactin difference has been found in 
normal man (8). It is thus highly unlikely that prolactin 
elimination in liver cirrhosis is substantially different 
from (or lower than)that in the normal situation. Definite 
proof, however, will be provided by MCR studies using puri-
fied human prolactin in patients with cirrhosis of the 
liver. In order to find out whe~r the way in which pro-
lactin is eliminated in liver cirrhosis is specific for 
this hormone or is a more general way of polypeptide hor-
mone removal, we also studied in the same manner the 
removal by the liver and the kidney of growth hormone, a 
hormone closely resembling prolactin in molecular weight. 
In this study it was found that growth hormone is removed 
in a different way, as it is mostly eliminated by the li-
ver whereas no substantial growth hormone elimination 
takes place in the kidney. Growth hormone elimination by 
the liver is inversily related to the degree of liver 
failure in cirr!10sis of the liver. 
In fact the paradoxical rise of growth hormone after TRH 
stimulation in cirrhosis of the liver closely resembles 
the delayed reaction of prolactin secretion after TRH 
stimulation in patients with severe kidney disease (7). 
That the liver is very important in growth hormone elimi-
nation is further substantiated by the findings of 
Bratusch-Marrain et al (8) who reported that in normal man 
the liver accounts for approximately 50% of total growth 
hormone clearance. As growth hormone is implicated in 
somatomedin production by the liver the different metabolic 
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fate of human growth hor@one and prolactin may mean that 
prolactin has a specific biologic effect on the kidney. It 
has been found that in the rat prolactin is mainly taken up 
by the proximal tubular cells from the glomerular filtrate 
(10). Since almost no prolactin is excreted in the urine 
(11), the hormone is probably broken down in the epithelium 
of the proximal tubules. In view of the effects of prolac-
tin on water and electrolyte metabolism in lower animals, 
a specific effect of prolactin in volume homoiostasis has 
been suggested (12). However, as pointed out in the intro-
duction, the evidence presented uptill now in man is scanty 
and inconclusive and a definite answer must be provided 
by further studies. On the basis of the observation that 
prolactin levels rise excessively after TRE stimulation 
(1,2,3) and that the normal diurnal prolactin secretion 
pattern may be lost in cirrhosis of the liver it is proba-
ble that the hyPe~olactinemia of chronic liver disease is 
not caused by a decreased metabolic clearance rate but by 
an abnormality in the control of prolactin secretion. 
Prolactin secretion by the anterior pituitary is tonically 
inhibited by hypothalamic dopamine (14). Thus the increased 
prolactin release in cirrhosis of the liver could possibly 
be caused by changes in dopaminergic activity in the cen-
tral nervous system. This might be effectuated by a dis-
turbance of hypothalamic dopamine secretion through inter-
ference with neurotransmitter precursor/amino acid levels 
and/or the formation of false neurotransmitters (15,16), 
while dopamine secretion may also be influenced by the 
elevated plasma estrogen levels in cirrhosis of the liver 
(17,18). In addition estrogens have a direct stimulating 
effect on prolactin secretion by the pituitary (19). In 
order to test these various possibilities we used a rat 
model of portal hypertension in which hepatic mass was 
preserved and in which a possible prolactin stimulating 
effect of alcohol was eliminated. Prolactin levels were 
found to be significantly 
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raised in the rats. In this model, changes in plasma amino 
acids created by diet manipulation, did not influence pro-
lactin secretion. However the induction of portal hyper-
tension itself also did not influence plasma amino acid 
levels while it did raise prolactin levels. It thus seems 
possible that this model, in which hepatic integrity is 
maintained, cannot be used to test the neurotransmitter/ 
amino acid hypothesis. Furthermore, prolactin secretion 
after TRH stimulation in hepatic encephalopathy was found 
to be higher than in cirrhosis of the liver without ence-
phalopathy (20). Hepatic encephalopathy only occurs in man 
when liver function is severely impaired. Evidence has 
been put forward that in hepatic encephalopathy hypotha-
lamic dopamine release may be disturbed, possibly through 
the formation of false neurotransmitters (15,16). This 
disturbance of central dopaminergic systems and the possi-
ble formation of false neurotransmitters are thought to 
be caused by a change in the ratio of plasma branched 
chain to plasma aromatic amino acids towards increased 
aromatic amino acids. Since both branched chain and aro-
matic amino acids compete for transport through the blood-
brain barrier by the same carrier (21,22) this change 
will express itself in changed amino acids levels in the 
brain. Evidence in favour of this hypothesis is formed by 
the reported effectiveness of amino acid mixtures designed 
to counteract this deranged amino acid ratio (23,24). In our 
own stut~ reported in chapter 6 we confirm the disturbed 
amino acid pattern found in chronic hepatic encephalopa-
thy, while this pattern normalized after infusion of amino 
acid mixtures with excess branched chain amino acids.At 
the same time prolactin levels after TRII stimulation were 
either normalized or substantially lowered. We thus pro-
vide indirect evidence that in hepatic encephalopathy 
a disturbance in CNS neurotransmitters (probably dopamine) 
systems causes the increased prolactin secretion. In view 
of the finding that the false neurotransmitter octopamine 
does not have an effect on prolactin release by the pitui-
tary gland in vitro and also does not influence the pro-
lactin secretion inhibiting effect of dopamine in vitro 
(Lamberts and HacLeod, unpublished observations) , it 
seems less likely that the disturbance in CNS neurotrans-
mitter systems responsible for the hyperprolactinemia in 
cirrhosis of the liver and encephalopathy includes the 
formation of false neurotransmitters. Although our rat 
model possibly was not suitable to test the amino acid 
neurotransmitter hypothesis it proved eminently suitable 
to test the elevated estrogen hypothesis, as both prolac-
tin and estradiol-17B were found to be significantly 
raised in the portal hypertensive rats. Castration, which 
caused lower plasma levels of estrogens in the male rat, 
significantly decreased peripheral prolactin levels and 
completely blocked the portal hypertension-·induced hyper-
prolactinemia, while suppletion with dihydrotestosterone 
did not influence the castration-induced fall in pitui-
tary prolactin and plasma prolactin levels. This suggests 
that the ~feet of castration on prolactin levels is me-
diated by changes in estrogen levels rather than by the 
decreased testosterone levels. Furthermore we found that 
the elevated plasma estradiol-17B and plasma and pituitary 
prolactin levels found in the portal hypertensive rats 
were associated with significantly decreased hypophysial 
stalk plasma dopamine levels. Estrogen levels are very 
often raised in cirrhosis of the liver with portal hyper-
tension, mainly because of increased peripheral aromatiza-
tion of testosterone via androstenedione (25,26). It has 
been shown that estrogens stimulate prolactin levels in 
man and rats and that they enhance the effect of TRH 
stimulation on prolactin release through interference 
with hypothalamic dopamine release and an action on the 
pituitary dopamine receptor (18,19,27). We thus provide 
evidence that the elevated estrogen levels associated 
with portal hypertension and cirrhosis of the liver may 
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cause hyperprolactinemia through interference with the 
hypothalamic release of dopamine. That this mechanis~ 
probably also plays a role in cirrhotic patients can be 
concluded from the study described in chapter 7, in which 
it was found that the prolactin secretion after TRH sti-
mulation in ~ale cirrhotic patients with evidence of 
clinical hyperestrogenismus could be significantly lov;ered 
by the administration of the antiestrogen tamoxifen, a 
drug that blocks the effect of estrogens through competi-
tion at the estrogen receptor (28). Although the patients 
in this study were not followed for a long time, a remark-
able clinical improverr>ent of painful gynecomastia was 
found in sorr>e individual patients. This brings us to the 
question whethcrany clinical implications can be derived 
from these studies. On theoretical grounds, the observa-
tions made in some patients and the fact that uptill now 
no significant side effect of tamoxifen have been descri-
bed, it seems to be worthwhile to conduct a trial of this 
drug in the gynecomastia and impotence associated with 
cirrhosis of the liver, provided that patients refrain 
from drinking alcohol, snce alcohol may influence both 
prolactin secretion and testicular function directly (29). 
The gynecomastia of cirrhosis of the liver may be asso-
ciated with normal or elevated prolactin levels (30) but 
is more often associated with a change in the estrogen/ 
testosterone ratio occuring in this condition (31,32). 
It is however very interesting in tlis respect that an 
elevated estrogen/decreased testosterone ratio has been 
found to enhance prolactin receptor activity (33). It 
thus seems likely that a combination of various subtile 
hormonal changes lead to gynaecomastia. Since the elevated 
estrogen levels seem to play a pivotal role, the choice 
of tamoxifen to combat this condition seems appropriate. 
Finally it is highly unlikely that prolactin is the only 
pituitary hormone influenced in cirrhosis of the liver 
and possibly the disturbance of prolactin is an example 
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of a more general hypothalamic/pituitary disorder. It 
seems interesting to extend studies to the role of fiSH in 
cirrhotic patients with increased skin pigmentation (34) 
and to the search for the elusive hypothalamic factor 
thought to play a role in aldosterone secretion (35) , es-
pecially in patients with ascites and/or the hepatorenal-
syndrome since in both cases dopamine has been implicated 
as a neurotransmitter. I'Jhen we return to the questions we 
set out to answer we may conclude that: 
1. The liver is not important in prolactin elimination 
and prolactin degradation in chronic liver disease is 
probably normal. 
2. The degradation of prolactin is different from that of 
a comparable polypeptide hormone, growth hor-mon_e, as 
it is mainly eliminated by the kidney, while growth 
hormone is mainly eliminated by the liver. This diffe-
rent metabolic fa-Le may be the consequence of a biolo-
gic action of these horreones on these respective or-
gans. 
3. Central prolactin release may be disturbed ,both by 
increased estrogens levels, which interfere with hypo-
thalamic dopamine secretion and impaired CNS dopamine 
release through altered amino acid/neurotransmitter 
precursor levels. 
4. The rat with portal hypertension but without concomit-
tant liver disease has been found to exhibit reany of 
the hormonal changes associated with cirrhosis of the 
liver including the hyperprolactinemia. 
5. The hyperprolactinemia of compensated liver cirrhosis 
is probably caused by elevated estrogen levels, apart 
from a possible direct effect of alcohol on prolactin 
secretion, while the more excessive hyper-prolactinemia 
of hepatic encephalopathy points to a more complicated 
disturbance of CNS neurotransmitter systems possibly 
in part caused by changed amino acid/neurotransmitter 
precursor levels. 
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SUMMARY~ 
Prolactin levels in liver cirrhosis may be elevated, es-
pecially after TRH stimulation. In chapter 3 we presented 
evidence that these elevated prolactin concentrations are 
not caused by diminished prolactin elimination, since 
this elimination takes place mainly in the kidney both in 
patients with and without liver disease, while in other 
studies no substantial prolactin elimination by the normal 
liver was found. The manner in which prolactin is elimina-
ted in the kidney seems to be specific for this hormone, 
since growth hormone, a comparable polypeptide hormone, 
was found to be mainly removed by the liver, as described 
in Chapter 4. This different metabolic fate may reflecton 
different biological actions of both hormones on their 
respective target organs. From these studies, the exces-
sive rise of PRL after TRH stimulation and the reported 
loss of the normal diurnal PRL secretion pattern it fol-
lows that the hyperprolactinemia of chronic liver disease 
is not caused by a decreased metabolic clearance but by an 
abnormality in the control of prolactin secretion. Since 
prolactin secretion is mainly regulated by a tonic inhibi-
tion of secretion by hypothalamic dopamine, a disturbance 
of central dopaminergic systems was postulated, either 
th~ough elevated estrogen levels found in patients with 
cirrhosis of the liver or because of the deranged amino-
acid neurotransmitter precursor levels found in these pa-
tients. In Chapter 5 a study in male portal hypertensive 
rats is described in which an increased prolactin secre-
tion was found to be associated with elevated serum 
estradiol-17 B levels and decreased hypothalamic dopamine 
release. This increase in PRL secretion could be complete-
ly blocked by castration, which removes the major estrogen 
source in male rats. In chapter 7 we showed that elevated 
estrogen levels may also play a role in the hyperprolac-
tinemia of livercirrhosis in man, especially when 
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gynecomastia is present. On the other hand ~he changes in 
aminoacid/neurotransmitter precursor levels associated 
with cirrhosis of the liver and hepatic encephalopathy may 
be important in causing the even higher prolactin secre-
tion often found in this condition. In the portal hyper-
tensive rat model described in chapter 5 no effect of 
dietary induced aminoacid changes on prolactin release 
could be found. However, in this model hepatic mass and 
function is preserved, whereas hepatic encephalopathy only 
occurs in man when liver function is seriously disturbed. 
Furthermore in chapter 6 we presented evidence that the 
disturbed aromatic amino acid/branched chain amino acid 
ratio found in hepatic encephalopathy is indeed associated 
with abnormal prolactin secretion and can be influenced 
by normalization of this abnormal ratio. From these fin-
dings we conclude that the elevated prolactin levels found 
in liver cirrhosis are caused by an abnormality in the 
secretion of Prolactin. This abnormal secretion is proba-
bly caused both by increased estrogen levels especially 
in patients with concurrent gynecomastia and by a dis-
turbance in serum aminoacid/neurotransmitter precursor 
levels, especially in patients with concurrant hepatic 
encephalopathy, through interference with hypothalamic 
dopamine release. 
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SAMENVATTING. 
Serum prolactine spiegels zijn vaak matig verhoogd bij pa-
tienten met levercirrhose, vooral na stimulatie met TRH. 
In hoofdstuk 3 wordt aannemelijk gemaakt dat deze verhoog-
de prolactine concentraties niet worden veroorzaakt door 
een verminderde afbraak, aangezien de afbraak van prolac-
tine voornamelijk in de nier blijkt ~laats te vinden zowel 
bij patienten zonder als bij patienten met levercirrhose. 
Bovendien werd door anderen geen belangrijke afbraak van 
prolactine in de normale lever gevonden. De manier waarop 
prolactine door de nier wordt verwijderd lijkt specifiek 
te zijn, aangezien het vergelijkbare polypeptide hormoon 
groeihormoon juist wel voornamelijk door de lever wordt 
verwijderd, zoals beschreven in hoofdstuk 4. Dit verschil 
in eliminatie kan mogelijk wijzen op een verschillend 
biologisch effect van beide hormonen op hun respectieve-
lijke eliminatie organen. Door deze studies, de excessieve 
stijging van prolactine na TRH-stimulatie en het door ande-
ren aangetoonde verlies van het normale dagelijkse secre-
tiepatroon van prolactine wordt het aannemelijk dat niet 
een verminderde metabolic clearance rate maar een toename 
van de secretie van prolactine de oorzaak is van de ver-
hoogde prolactine spiegels. Aangezien de secretie van 
prolactine voornamelijk wordt gereguleerd door de tonische 
inhibitie van het door de hypothalamus afgegeven catecho-
lamine dopamine, ligt een verstoring van de centrale dopa-
mineafgifte voor de hand. Deze verstoring zou zowel ver-
oorzaakt kunnen worden door de verhoogde oesbogeenspiegels 
die bij levercirrhose gevonden worden als door een versto-
ring van aminozuur/neurotransmitterprecursor spiegels, die 
vooral bij een ernstige verstoring van de leverfunctie 
optreedt. In hoofdstuk 5 wordt een studie in een model van 
portale hypertensie in de rat beschreven waarin een ver-
hoogde prolactine secretie werd gevonden in associatie met 
verhoogde estradiol-17 B spiegels en een verlaagde hypo-
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thalame afgifte van dopamine. Deze toename van de prolac-
tine secretie kan volledig worden geblokkeerd door cas-
tratie, waardoor de belangrijkste oestrogeenbron in manne-
lijke ratten wordt verwijderd. In hoofdstuk 7 werd aange-
toond dat verhoogde oestrogeenspiegels bij levercirrhose 
waarschijnlijk ook een rol spelen bij het veroorzaken van 
hyperprolactinemie bij de mens, vooral wanneer er eveneens 
gynecomastie bestaat. Daar tegenover zijn veranderingen in 
de serum aminozuur samenstelling zoals deze beschreven wor-
den bij levercirrhose met hepatische encephalopathie moge-
lijk ook van belang voor het ontstaan van hyperprolactine-
mie. In het rattemodel van portale hypertensie beschreven 
in hoofdstuk 5 werd geen effect gezien op de prolactine 
secretie van manipulatie van de aminozuur samenstelling 
van het serum door beinvloeding van het dieet. In dit model 
blijft de leverfunctie echter grotendeels behouden terwijl 
in hepatische encephalopathie bij de mens de leverfunctie 
over het algemeen sterk gestoord is. Bovendien wordt in 
hoofdstuk 7 aannemelijk gemaakt dat een verstoorde aroma-
tische aminozuur vertakte-keten-aminozuur verhouding inder-
daad samengaat met een toegenomen prolactine secretie ter-
wijl normalisering van deze verhouding door toediening van 
aminozuur oplossingen met overmaat vertakte ketens de 
prolactine secretie eveneens grotendeels normaliseert. Uit 
deze bevindingen werd de conclusie getrokken dat de ver-
hoogde prolactine spiegels welke bij levercirrhose worden 
aangetroffen, veroorzaakt worden door een abnormale pro-
lactine secretie. Dit abnormale secretie patroon wordt 
waarschijnlijk veroorzaakt zowel door toegenomen oestro-
geenspiegels in het bloed, vooral bij patienten met gyne-
comastie, als door een verstoring van de serum aminozuur-
spiegels, vooral bij patienten met hepatische encephalopa-
thie. Beide factoren beinvloeden de prolactine secretie 
door een remming van de hypothalame doparr.ine afgifte. 
VERANTWOORDING. 
In een periode van bezuiniging on algemeen maatschappelijk 
zowel als academisch terrein wordt de periode, beschikbaar 
voor het bewerken van een proefschrift, in veel gevallen 
beperkt tot de periode, die, in het kader van een specialis-
tenopleiding, in een academisch milieu wordt doorgebracht. 
Dit betekent voor een internist in opleiding dat een 
onderzoek en de beschrijving hiervan in een periode van 
5 jaar moet worden verricht. oat lijkt lang, maar is in 
de praktijk kort. In feite moet alles meezitten. Men moet 
geluk hebben. De oorspronkelijke vraagstelling moet blijken 
zinnig geweest te zijn, bepalingen en protocollen moeten 
worden ontwikkeld en gestandariseerd, en de uiteindelijk 
bereikte resultaten moeten liefst ook nog houtsnijden. 
Het zal duidelijk zijn, dat hulp op alle denkbare terreinen 
dan ook onontbeerlijk is; waarbij een zinnig en selectief 
gebruik maken van de aangeboden hulp misschien wel de meest 
noodzakelijke eigenschap van de jonge onderzoeker moet zijn. 
In mijn geval heeft het aan hulp niet ontbroken. Prof. 
Frenkel, die mij in opleiding nam en mij zodoende, naast 
mijn internistische vorming, gelegenheid gaf tot het ver-
richten van wetenschqppelijk onderzoek, vervolgens Steven 
Lamberts en Paul Wilson die gezamenlijk, geholpen door grote 
kennis van zaken, dit " gat in de markt " ontdekten en 
vervolgens enthousiast en stimulerend geholpen hebben het 
te exploiteren. Zelden zal een promovendus een zo gemakke-
lijk, veelvuldig en vriendschappelijk contact met zidn 
promotoren hebben gehad. Vervolgens Wim de Greef en Frank 
de Jong en vooral Piet Uiterlinden, John Zuiderwijk, Ellen 
Bons, Theo Verleun en }1arlijn Zandvoort van het laborato-
rium Interne III, die allen op uiterst nauwkeurige wijze 
essentiele bijdragen aan dit proefschrift hebben geleverd. 
Grote bewondering heb ik ook voor het uithoudingsvermogen 
van Wim van den Berg, Felix de Rooy en alle andere mede-
werkers van het laboratorium Interne II die hebben getracht 
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mij de beginselen van de laboratorium technologie bij te 
brengen, zonder daarbij het noodzakelijk gevoel voor humor 
en betrekkelijkheid te verliezen. Voorts dank aan de 
afdeling rontgenologie voor hulp bij de catheterisaties en 
aan Rene van Zanten voor hulp bij de ratteoperaties. Ten-
slotte heb ik voor de vormgeving van het uiteindelijke 
proefschrift veel te danken aan Marieke Horsch-Blecking 
en later aan Trudi van Campenhout-Pors, die nauwgezet al 
het noodzakelijke tikwerk hebben verricht. Ik realiseer 
me dat velen, die allen op hun wijze, direct of indirect, 
hebben bijgedragen aan het tot stand komen van dit proef-
schrift onvermeld zullen blijven. Hun bijdrage is hierdoor 
zeker niet minder belangrijk; uiteindelijk is de vriend-
schap en steun van velen op de achtergrond onontbeerlijk. 
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CURRICULUM VI'1'AE 
De schrijver van dit proefschrift werd geboren op 4 nove~­
ber 1947 te ~msterdam. In Hilversum werd het lager en 
middelbaar onderwijs genoten. In 1965 werd het eindexamen 
Gymnasium B aan het Hilversums Gymnasiu~ behaald. In 1965 
werd de ~edicijnen studie aangevangen aan de Universiteit 
te Leiden, alwaar in 1971 het doctoraalexamen, en in 1973 
het artsexamen werden behaald. In verband met uitzending 
naar de tropen werden in 1973 en 1974 assistentschappen 
gynaecologie, verloskunde en chirurgie gevolgd in het 
ziekenhuis St.Antoniushove te Leidschendam en aansluitend 
de nationale tropencursus voor artsen aan het Koninklijk 
Institu~t voor de tropen te A~sterdam. In 1975 en 1976 was 
de schrijver District Medical officer in het Qachesnek-
district in Lesotho. Na terugkeer uit Afrika werd de op-
leiding tot internist aangevangen onder leiding van Pro-
fessor M.Frenkel. In december 1981 werd de schrijver in 
het specialistenregister ingeschreven. Hij is thans werk-
zaam als internist in het Havenziekenhuis te Rotterdam. 
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